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Abstract
Identifying Mechanisms of Drug Tolerance in EGFR Mutant Lung Cancer

Bomiao Hu

2021

The majority of EGFR mutant lung adenocarcinomas respond well to EGFR tyrosine kinase
inhibitors (TKIs). However, most of these responses are partial with drug tolerant residual
disease remaining even at the time of maximal response. This residual disease serves as a
reservoir for the emergence of acquired resistance and tumor relapse, which inevitably occurs in
patients treated with TKIs. It is thus critical to understand the biology of residual tumor cells and
find out the mechanisms that underlie drug tolerance. Knowledge of such mechanisms could
lead to the identification of potential strategies to forestall the emergence of drug resistance.
Studies of residual disease have been hampered by the difficulty of studying these persister
cells in patient specimens and most studies to date have relied on analysis of established cell
lines in culture. To investigate the cellular and molecular properties of residual tumor cells in
vivo, we leveraged patient-derived models of EGFR mutant lung cancer. Three EGFR mutant
PDXs were treated with the third-generation TKI osimertinib. Tumors regressed in all cases but
measurable residual tumor remained in 2 out of the 3 PDXs even after 6 weeks of osimertinib
treatment. Whole-exome sequencing (WES) of the untreated PDXs compared to the residual
tumors revealed an unchanged mutational landscape between the samples, indicating that
genetic mechanisms did not account for drug tolerance. Bulk RNA-sequencing, however,
demonstrated extensive transcriptional changes between the untreated PDX and residual
disease. In one of the PDXs, we identified upregulation of the neuroendocrine lineage
transcription factor ASCL1 in residual disease compared to untreated tumors. Using single-cell
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RNA-sequencing we found a pre-existing ASCL1hi tumor cell population in untreated tumors,
suggesting that these cells which possessed drug tolerant properties were selected for during
drug treatment. Depending on the cell line examined, expression of ASCL1 in human mutant
EGFR lung cancer cell lines gave rise to persister clones following osimertinib treatment. This
result demonstrated functionally that ASCL1 could lead to TKI tolerance and that whether it did
this depended on the cellular context. Further gene expression profiling of ASCL1-transfected
cell lines identified an ASCL1-induced epidermal-to-mesenchymal transition (EMT) signature
that potentially resulted in tolerance to osimertinib. Our studies provide insights into the role of
the neuroendocrine factor ASCL1 as a potential driver of drug tolerance in mutant EGFR lung
cancer and ongoing work is focused on identifying the mechanisms underlying the cellular
context specificity of ASCL1-mediated EMT.
In addition to PDX models, we also performed complementary studies on TKI tolerance in a
genetically-engineered mouse model (GEMM) of mutant EGFR-driven lung adenocarcinoma. To
identify and isolate drug tolerant persisters, we developed a transgenic mouse model in which
mutant EGFR-expressing lung epithelial cells were labelled with a fluorescent marker, mKate.
Using this model, we found that tumor-bearing mice responded almost completely to osimertinib
and the number of mKate+ cells was decreased in response to TKI treatment and plateaued
after 4 weeks of treatment. Targeted deep sequencing of the mutant EGFR transgene did not
show enrichment of any resistance conferring mutations in mKate+ cells following TKI
treatment, indicating that on-target EGFR mutations did not contribute to TKI tolerance in the
GEMM. In contrast, RNA sequencing of DTPs sorted from this model revealed deregulation of
metabolic and developmental pathways that could play a role in drug tolerance.
In summary we have established and characterized state-of-the-art in vivo models to study
drug tolerance and unveiled new potential mechanisms of TKI tolerance which serve as the
foundation for future studies into this critical problem in cancer therapeutics.
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CHAPTER 1: LITERATURE REVIEW
Lung Cancer
Statistics
Lung cancer is currently one of the most commonly diagnosed cancers and the leading
cause of cancer-related death in the US [1]. In 2021, there are estimated to be more than 230K
new cases and 130K deaths from lung cancer in the US. The incidence of lung cancer has been
steadily reduced by 2% per year since mid-2000s and the death rates have been decreased by
54% in men and 30% in women compared to their respective historical highest rates, which is
partially due to public efforts to decrease cigarette smoking and improved screening and
treatment options including targeted therapy [1, 2]. However, despite all these improvements,
the overall 5-year survival rate for lung cancer is only 21%, much below the average rates for all
cancer types taken together [1]. Most of the lung cancer cases (83%) are diagnosed at an
advanced stage, with regional or distant metastasis, which negatively impacts treatment efficacy
and prognosis.

Histological Classifications
Lung cancer is collection of multiple diseases. Based on the histological features lung
cancer is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC) and the latter can be further divided into three groups: lung adenocarcinoma (LUAD),
lung squamous cell carcinoma and large cell lung carcinoma [3]. The incidence rates for each
subtype are illustrated in Figure 1.1. Lung adenocarcinoma is by far the most common
histological subtype of lung cancer, accounting for 40% of all lung cancer cases, usually arising
in the lung periphery close to terminal bronchioles and alveoli and shows features of glandular
differentiation. On the other hand, squamous carcinoma is localized more centrally in the lungs
near the bronchus and characterized by keratinization [3]. Small cell lung cancer is distinct from
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the other cancer types in that it is thought to arise from neuroendocrine (NE) cells of the lungs
and show positivity for NE marker staining such as chromogranin A and synaptophysin.

Figure 1.1 Histological classification of lung cancer, adapted from [3]

Driver Mutations in Lung Adenocarcinoma
Studies of the genetics and biology of LUAD have brought tremendous insights into the
understanding of this disease. Various driver mutations have been identified and the functions
of these mutated oncogenes have been elucidated and translated into improvements of clinical
practice [4]. The most commonly mutated oncogene in LUAD is KRAS, with mutations occurring
in 30% of all LUAD cases (Figure 1.2). These mutations lock KRAS in a GTP-bound active
state and prevent GTP hydrolysis [5]. Therefore, the mutant form of KRAS is able to transduce
constitutive downstream growth signals, leading to uncontrollable cell proliferation. The second
most common oncogenic mutations occur in EGFR and the mutated forms are found in 10-15%
of LUADs in Caucasians and in even higher incident rates in East Asians (Figure 1.2). The
majority of these LUAD-associated EGFR mutations fall into two different locations in exons
encoding the kinase domain of EGFR: one is single nucleotide substitution in exon 21, leading
to a leucine-to-arginine transition at codon 858 (L858R); the other is a set of short in-frame
deletions in exon 19, resulting in a loss of 4-6 amino acids in the N-lobe of EGFR kinase domain
(del19).
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Structural analyses of these EGFR mutants have determined the biochemical
consequences of these alterations. The L858R mutation resides in the activation loop of EGFR
kinase domain and this amino acid substitution destabilizes its inactive conformation [6]
whereas exon 19 deletion mutations are in proximity to the αC helix and in the truncated
mutants αC helix is pulled towards the catalytic site, thus stabilizing the active conformation [7].
Both forms of the EGFR mutations result in constitutive activation of the EGFR kinase and
uncontrolled transduction of growth signals, which is similar to the consequences of KRAS
mutations identified in LUAD.
Beside KRAS and EGFR mutations, other less common oncogenic driver mutations have
been gradually identified in recent years to fill in the mutational spectrum of LUAD (Figure 1.2),
including BRAF V600E mutation, ALK translocation, ROS1 rearrangement etc. It is worth noting
that all of these mutated oncogenes are centered at RTK-MAPK signaling pathways,
highlighting the importance of these pathways in the growth and survival of LUAD. Many of
these oncogenic drivers are druggable targets and targeted therapies have been approved or in
clinical trials [8-11].

Figure 1.2 Driver mutations in LUAD, adapted from [4]

Treatments for Non-Small Cell Lung Cancer
Surgery
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Surgery can be a good option for patients with overall good health and early-stage NSCLC
[12]. Since the lesions are usually local and cancer cells are less aggressive, removing the
tumor area all together provides the best chance for cure. For diseases in advanced stages,
lesions cannot be completely removed through surgery and therapeutic agents are thus
necessary for controlling the disease progression. In rare cases where tumor cells form single
distant metastasis (for example, in the brain) and tumors in the lungs are manageable, surgery
can be used to resect metastatic lesions, followed by treatment of cancers in primary sites.
Patients usually receive adjuvant chemotherapy to eliminate any tumor cells left over and to
reduce recurrence. Neoadjuvant therapy is also used under certain scenario to reduce tumor
burden and improve the outcome of subsequent surgical procedures.

Chemotherapy
Chemotherapy is a common therapeutic option for NSCLC in general and can be used
either alone or in combination with other types of therapies. It historically has been one of the
major treatment options for patients where no driver mutations are identified or targeted
therapies are not available (for example, cancers driven by mutant KRAS) and now is frequently
used in combination with immunotherapies [12].
Chemotherapy drugs like platinum-based drugs and taxanes are cytotoxic reagents that
interfere with DNA synthesis or microtubule functions, both of which are critical biological
processes for rapidly-proliferating cells including cancer cells. Due to the lack of specificity
against malignant cells, chemotherapy agents can cause various side effects on multiple organs
and systems that require constant cell proliferation and renewal, such as the digestive and
hematopoietic systems, limiting the dose and duration of such treatments.

Immunotherapy
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In recent years, immune checkpoint inhibitors (ICIs) have become one of the main classes
of drugs used to treat NSCLC. Tumor microenvironment is usually immunosuppressive and the
normal cytotoxic functions of T cells are silenced by immune checkpoint proteins mostly
expressed on surface of tumor cells. The idea of this drug family is to activate immune system
to target cancer cells by blocking the inhibitory interactions between checkpoint receptors and
ligands expressed in immune cells and tumor cells respectively. The major checkpoint pathways
involved in the context of cancer are mediated by PD1 and CTLA4, which are the drug targets
for immune checkpoint inhibitors [13].
Three classes of ICIs targeting PD1, PD-L1 or CTLA4 have been approved to treat patients
with advanced NSCLC. Despite the fact that a proportion of patients exhibit durable responses
to ICI treatment and improved overall survival as compared with chemotherapy, a large number
of patients do not show objective response at all and the determinants of response to
immunotherapy in NSCLC are still under investigation. Some retrospective studies suggest that
patients with higher tumor mutational burden might benefit more from immunotherapy as
nonsynonymous somatic mutations tend to produce more neoantigens that facilitate recognition
of tumor cells by immune system [14, 15].
Similar to other therapies for NSCLC, patient develop acquired resistance to ICIs as well,
which may arise through different mechanisms [13]. One prominent mechanism of resistance to
immunotherapy is impaired antigen presentation in tumor cells, mainly through loss of functional
β2-microglobulin, which results in defective MHC I molecules [16, 17]. Besides antigen
presentation deficiency, other tumor cell intrinsic signaling pathways and dysfunction of T-cells
are also implicated in driving ICI resistance [18].

Targeted Therapy
During the past few decades, genetic profiling of patient tumors has identified subgroups of
patients with genetic abnormalities that create vulnerabilities to drugs targeting certain gene
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products [8-11, 19, 20]. These genetic alterations occur in certain oncogenes and cancers
driven by these mutants become dependent on the activity of the oncogenes. These oncogenic
drivers thus serve as drug targets. Unlike chemotherapy, the action of the targeted therapy is
usually more restricted to cancer cells. Therefore, targeted therapy usually shows fewer side
effects and higher efficacy compared to traditional chemotherapy when given systemically to
patients whose tumors harbor the relevant drug targets [20].
Many oncogenic drivers identified in LUAD, the most common subtype of NSCLC, are
druggable (Figure 1.2). Besides EGFR, which stands out as the most frequently mutated
targetable driver oncogene, other oncogenic drivers including BRAF, ALK, ROS1 etc harbor
activating mutations as well, which render the cancer cells dependent on the constitutive activity
of these oncogenic mutants. Indeed, clinical trials for the kinase inhibitors hitting these targets
have shown promising outcomes in selected patient populations [8-11, 19, 20] and a number of
targeted drugs have been approved as first-line therapy for LUAD patients harboring these
activating mutations.
Nonetheless, as with all the other cancer treatments, acquired resistance to targeted
therapy is inevitable in lung cancer patients [21]. Mechanisms of resistance generally fall into
two categories: on-target and off-target. On-target resistance is caused by secondary mutations
in the original drug targets. The resistance conferring mutations are able to reduce the efficiency
of drug binding and lead to reactivation of the oncogenic drivers through changing the affinity of
the kinase for ATP or creating stearic hindrance [22, 23]. Examples of on-target mechanisms
include the EGFR T790M mutation found in patients receiving first-gen EGFR TKIs and the
EGFR C797S found in patients treated with third-gen EGFR TKI osimertinib [24-27]. Off-target
resistance may result from activation of alternative signaling pathways that bypass the primary
drug targets, such as MET and ERBB2 amplification identified in TKI-treated EGFR mutant lung
cancer patients [21, 28], or transition to another cell lineage that no longer depends on the
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original oncogenes for survival, such as SCLC transformation and epidermal-to-mesenchymal
transition (EMT) driving acquired resistance to EGFR TKIs [29].

EGFR TKI Therapies in Mutant EGFR Lung Cancer
Since LUADs driven by EGFR mutants are addicted to the constitutive signaling activity of
EGFR pathway, lung tumor cells harboring EGFR activating mutations become sensitive to
EGFR TKIs, which lead to clinical trials and official approval of EGFR TKIs as first-line therapy
for EGFR-driven lung cancer [19, 20]. The schema shown in Figure 1.3A indicates the EGFR
TKI therapies that a patient would receive after being diagnosed with mutant EGFR lung cancer.
Initially, these patients have been treated with 1st or 2nd gen TKIs for about a year until they
acquired resistance to these drugs. The mechanisms of resistance to 1st and 2nd gen TKIs were
well studied (Figure 1.3B): the most frequent mechanism is secondary gatekeeper mutation
T790M in active center of EGFR kinase domain, which results in an increase in the binding
affinity for natural substrate ATP, outcompeting the drugs from their binding pocket [22]. Other
less common resistant mechanisms include activation of bypass signaling molecules in other
RTK pathways such as MET/ERBB2 gene amplification and PI3K activating mutations, as well
as histological transformation and phenotypic transition such as SCLC transformation and EMT
[30].
To overcome T790M-mediated acquired resistance, 3rd gen TKI osimertinib was designed
to specifically target and bind irreversibly to EGFR mutants [31, 32]. T790M+ patients with
acquired resistance to 1st or 2nd gen TKIs will benefit from this drug for about another year
before they become resistant again. The resistant mechanisms for osimertinib in 2nd line therapy
have been gradually elucidated in the past several years [33, 34]. The general types of resistant
mechanisms are very similar to what has been observed in patients treated with 1st and 2nd gen
TKIs, although the distribution of specific mechanisms is different between the two scenarios
(Figure 1.3C). On-target resistance conferring mutations were also identified in patients
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receiving osimertinib: C797 and L718 were the most frequently mutated amino acid residues in
osimertinib resistant tumors. C797S/G replaces the residue that osimertinib covalently binds to,
thus dramatically reducing the efficiency of kinase inhibition [26, 27] whereas L718V/Q leads to
bulkier side chains within the catalytic site that create steric hindrance for osimertinib [23].

Figure 1.3 EGFR TKI therapies approved for mutant EGFR lung cancer and mechanisms of acquired
resistance to EGFR TKIs. (A) Summary of clinical use of EGFR TKIs in EGFR mutant lung cancer. (B-C)
Mechanisms of acquired resistance to (B) 1st/2nd gen TKIs [30] and (C) 2nd line osimertinib [33,34].

Osimertinib has also been approved to be used in first-line therapy [19, 35]. Patients
receiving first-line osimertinib show longer progression free survival, compared to 1st or 2nd gen
TKIs (Figure 1.3A). However, they still inevitably develop acquired resistance. The resistant
mechanisms for osimertinib in first-line setting have just started to be investigated. An early
report on mechanisms of first-line osimertinib resistance in phase III FLAURA study suggest that
MET amplification and EGFR C797S mutation are most frequently seen in patients with
progressive disease as revealed by next-gen sequencing of circulating plasma DNA, although
what causes acquired resistance in the majority of patients (about 70%) remain unknown [36].
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More extensive research in clinical specimens as well as pre-clinical models is required to
elucidate the complex spectrum of resistant mechanisms and develop strategies to overcome
drug resistance.

Tolerance to EGFR TKIs in Mutant EGFR Lung Adenocarcinoma
Incomplete Response to EGFR TKIs
Lung adenocarcinomas driven by EGFR activating mutations become dependent on the
constitutive activity of EGFR and therefore patients harboring these mutations show greater
responses to EGFR tyrosine kinase inhibitors (TKIs) [37-39]. Three generations of EGFR TKIs
have been developed so far and five targeted small molecule reagents have been approved to
treat mutant EGFR lung cancer as first-line therapy. Third-gen TKI osimertinib, in particular, was
designed to overcome secondary drug resistant mutation T790M and specifically target mutant
EGFR, which spares wildtype EGFR and thus reduce potential side effects [31].
Despite the higher response rates and improved progression-free survival compared to
traditional chemotherapy, EGFR TKIs are still not able to cause complete tumor regression in
most cases, leaving a significant amount of tumor tissues even at the time point of maximal
response (Figure 1.4) [19]. These drug tolerant residual tumor cells that survive TKI treatment
serve as reservoir for relapse tumors, which is inevitable in patients receiving TKI therapies and
is the major reason for treatment failure. In this regard, understanding the biology of drug
tolerance may lead to identification of potential strategies to combat incomplete response and
delay acquired resistance.

Figure 1.4 Incomplete response to EGFR TKIs. Scan courtesy of Anne Chiang, MD, PhD
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Current Knowledge about Drug Tolerance in Mutant EGFR Lung Cancer
There has been extensive research on the persistent cancer cells in pre-clinical models of
multiple types of cancer and various mechanisms of drug tolerance have been identified so far
[40, 41].
Mutant EGFR lung cancer, in particular, has gained great research interest since drug
tolerance to EGFR targeted therapy is prevalent in patients and always leads to acquired drug
resistance. Studies of drug-tolerant persisters (DTPs) in established human EGFR mutant lung
cancer cell lines have uncovered several pathways that contribute to drug tolerance including
the NF-kB pathway and activation of NOTCH3 signaling through the non-canonical Wnt
pathway [42, 43]. Additionally, the epigenetic regulator KDM5A was found to lead to a drug
tolerant state that can be reversed upon TKI withdrawal [44] and upregulation of the antiapoptotic factor BCL2 was shown to promote survival leading to TKI-tolerant residual cells [45].
More recent findings suggest that activation of Aurora kinase A was able to promote cell survival
through mitigation of apoptotic program induced by EGFR TKIs [46]. Studies of the chromatin
structures in DTPs revealed a heterochromatin state mediated by repressive epigenetic
modifications, which facilitated cell survival through suppression of stress-induced LINE-1
expression [47].
Despite these findings mostly from in vitro studies, knowledge of which pathways are
responsible for drug tolerance in vivo in patients are still limited. Indeed, studying residual
disease has been particularly challenging in lung cancer, largely due to the difficulty of acquiring
patient specimens at the time of maximal response. A recent study on single-cell analysis of
TKI-treated patient specimen suggest that residual tumor cells exhibited an increased
expression of healthy lung alveolar gene signature, shedding light on a potential transition
between cell states upon development of drug tolerance [48]. In order to gain deeper insights
into the mechanisms of drug tolerance in EGFR mutant lung cancer using patient specimens,
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we leveraged patient-derived models to investigate the cellular and molecular properties of the
cancer cells that persist despite dramatic tumor regression induced by EGFR TKI treatment,
and to identify potential mechanisms of drug tolerance.

Pre-clinical Models of Mutant EGFR Lung Adenocarcinoma
Cell Line
Cell lines used in mutant EGFR lung cancer research are derived from patient tumors
harboring EGFR activating mutations (Table 1.1) [49] and play important roles in studying
biology and mechanisms of resistance to EGFR TKIs in vitro [50]. In my thesis research, I will
mainly focus on three human cell lines: PC9 (delE746-A750), H1975 (L858R+T790M) and
HCC827 (delE746-A750). All the three lines show sensitivity to third-gen EGFR TKI osimertinib.
Cell Line

EGFR mutations

PC9

delE746-A750

H1975

L858R + T790M

HCC827

delE746-A750

H3255

L858R

HCC4006

delL747-A750>P

Table 1.1 List of selected human mutant EGFR lung cancer cell lines

Patient-Derived Xenograft
Similar to human cell lines, patient-derived xenografts (PDXs) also originate from patient
specimens but are transplanted into immune-deficient mouse to have the tumor cells grow in
vivo. PDX models preserve many biological features of the primary patient samples, including
histology, drug sensitivity and diversity and heterogeneity of patient tumors [51, 52]. Such
models provide an opportunity to directly study patient tumor cells in vivo. Through co-analysis
of patient specimens and PDXs, we are able to obtain more clinically relevant information that
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eventually improves the understanding of the biology of mutant EGFR lung cancer and
treatment outcomes.
Despite the lack of a fully functional immune system in the murine host of PDX models, they
are largely used to investigate tumor cell intrinsic mechanisms of drug tolerance and resistance.

Genetically-Engineered Mouse Model
In genetically-engineered mouse model of mutant EGFR lung cancer, human mutant EGFR
is transduced into mouse genome and its expression is induced specifically in mouse lung
epithelial cells to transform them into adenocarcinoma cells [53]. The mutant EGFR-driven
mouse lung tumors retain the same TKI sensitivity as in human lung cancer patients. As the
tumors are developed in immune-competent mice, transgenic mouse models allow for studies
on cancer biology and drug tolerant mechanisms in the context of fully functional tumor
microenvironment. In addition, mutant EGFR can be crossed with other transgenic alleles to
investigate the roles of certain genes in tumor progression and drug resistance or add some
features to the tumor cells (for example, lineage tracing by fluorescent marker).
In my thesis research, I will use a modified GEMM of mutant EGFR lung cancer as well as
PDX models to perform complementary studies on the mechanisms of TKI tolerance.
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SUMMARY
EGFR activating mutations are present in about 10-15% of lung adenocarcinomas and
confer sensitivity to EGFR tyrosine kinase inhibitors. As a result of their efficacy in this patient
population, EGFR TKIs are the first-line targeted therapy for LUAD patients with EGFR mutation
positive tumors. Despite remarkable response rates to TKIs, tumor regression is not complete in
most patients treated with EGFR TKIs and tumor cells persist despite treatment. Most prior
studies have focused on understanding in vitro mechanisms of drug tolerance in human cell
lines and the nature of the incomplete responses in patient specimens is still not fully
understood. In order to learn more about the biology of residual cells in clinically relevant
conditions, we leveraged patient-derived models to study drug tolerant residual disease. This
chapter focuses on characterizing the PDX models and determining their capability to mirror
incomplete response in patients, as well as gaining insights into the cellular and molecular
properties of the PDX-derived drug-tolerant persisters. In a subset of PDXs that we tested, we
observed a significant number of human mutant EGFR lung adenocarcinoma cells that survived
osimertinib treatment. Subsequent cellular profiling of residual tumor cells indicated that, in
these specific PDXs, they entered a quiescent state with cell cycle arrest and a low level of
apoptosis. Through next-generation sequencing, we did not identify alterations in the mutational
landscape of residual tumors compared to untreated tumors that could account for their
persistence. However, we observed a dramatic change in the transcriptional profile between the
two conditions. Thus, in summary, we show that PDXs can be used to model tolerance to EGFR
TKIs.

INTRODUCTION
Mutations in the Epidermal Growth Factor Receptor (EGFR) gene are found in ~15% of lung
adenocarcinomas in the US and at higher frequencies in East Asian populations [4]. Tumors
harboring these mutations exhibit sensitivity to EGFR tyrosine kinase inhibitors (TKIs) [37-39]
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and five TKIs (erlotinib, gefitinib, afatinib, dacomitinib and osimertinib) are approved for the firstline treatment of this disease. However, even with all of these agents and despite response
rates of ~70-80%, tumors never regress completely and residual tumor remains [19, 20, 32].
These drug tolerant residual tumor cells then serve as reservoir for the subsequent emergence
of acquired resistance, which inevitably develops in patients receiving EGFR TKI therapy, even
with the TKI that has shown the greatest progression-free survival, osimertinib [26, 27, 33, 34].
Thus, it is critical for us to understand the mechanisms that underlie drug tolerance to develop
strategies to limit the amount of residual disease and delay tumor relapse.
Studies of drug-tolerant persisters (DTPs) have been mostly focused on established human
EGFR mutant lung cancer cell lines so far. Discoveries in vitro have uncovered various
mechanisms of drug tolerance, including signaling pathways promoting cell survival such as the
NF-kB pathway and NOTCH3 pathway [42, 43], repressive chromatin state through epigenetic
regulation [47], upregulation of the anti-apoptotic factor BCL2 [45], activation of cell cyclepromoting factor Aurora kinase A [46] and metabolic shifts to fatty acid oxidation and enrichment
of antioxidant program in cycling persisters [54]. However, mechanistic studies on TKI tolerance
in vivo, especially in a clinically relevant setting, have just started to emerge. A recent study on
single-cell analysis of EGFR TKI-treated patient specimens emphasized the role of both tumor
cell intrinsic and microenvironmental programs in drug tolerant residual disease [48]. Despite
the insights into drug tolerant mechanisms in human tumors, such study still has its limitation in
that it is challenging to acquire sufficient patient specimens at the time of maximal response and
the tumor cell abundance can vary between different specimens, which makes it difficult to
analyze and interpret the data. One solution to addressing these challenges is to grow patient
specimens as patient-derived xenografts (PDXs) in experimental animals like immunodeficient
mice. PDX models are likely to preserve the biological features of patient tumors, especially
tumor cell-intrinsic properties. The histological and pharmacological similarity between PDX and
corresponding patient specimen makes it a good model to identify residual disease and
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investigate drug tolerance in vivo. In this chapter, we characterized several mutant EGFR lung
cancer PDXs to determine whether they can be used to study drug tolerance and leveraged
these models to profile the cellular and molecular properties of the persistent cells and to
identify potential mechanisms of drug tolerance.

RESULTS
Identification of drug-tolerant residual disease in PDXs of EGFR-driven lung cancer
treated with the EGFR TKI osimertinib.
To determine whether we could observe and isolate residual disease grown in vivo, we
studied three EGFR mutant lung adenocarcinoma Patient-Derived Xenografts (PDXs). All of the
PDXs were grown from biopsies of tumors that had acquired resistance to first- or secondgeneration TKIs and all harbored an in-frame EGFR exon 19 deletion mutation and a secondary
T790M mutation in EGFR known to confer resistance to 1st and 2nd generation TKIs (Figure
2.1A-B). Analysis of the TKI sensitivity of these PDXs revealed that they were all resistant to the
first-gen TKI erlotinib (consistent with the clinical course in the patient) and sensitive to the thirdgen TKI osimertinib (Figure 2.1C-E and S2.1A-C). To determine whether residual cancer cells
were present in these PDXs following osimertinib exposure, we treated tumor-bearing mice with
osimertinib for 4-6 weeks and monitored tumor size on a weekly basis. We found that, although
YLR074 and YLR102 exhibited significant responses to osimertinib with an 85% decrease in
tumor volume by the end of week 6 on drug, the response was incomplete and residual tumor
remained. In contrast, YLR135 exhibited a complete response to osimertinib since its tumor
volume shrank by over 98.5% after 4 weeks of treatment. These results indicate that different
PDXs can exhibit variability in the depth of their response to osimertinib similar to that observed
in patients (Figure 2.1C-E).
To determine whether residual cancer cells were present, we collected tissue that remained
following treatment once the tumor volume had reached a stable plateau and the tumor was no
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longer shrinking (after 6 weeks of osimertinib treatment for YLR074 and YLR102 and 4 weeks
for YLR135). Histological analysis revealed that for all three of the PDXs residual lung
adenocarcinoma cells were present although the abundance of these cells was lowest in
YLR135 that had shown the greatest response to osimertinib (Figure 2.1F). In all cases, we
observed an increase in the stromal compartment in the residual disease sample. We confirmed
the presence of residual tumor cells following osimertinib treatment, by performing
immunohistochemical (IHC) staining for Nkx2-1, a lung epithelial cell marker (Figure 2.1G). In
addition, we also used an antibody that specifically recognizes the EGFR exon 19 DEL mutant
[55] present in YLR074 and YLR102 to further positively identify residual tumor cells (Figure
2.1H). These experiments revealed that PDXs can be used to model and identify drug-tolerant
disease. Considering the abundance of residual cells in YLR074 and YLR102, we used these
PDXs for subsequent studies.
Given that activity of the EGFR pathway is critical for tumor cell proliferation and survival in
EGFR-driven lung cancer [28, 56], we determined the levels of proliferation and apoptosis in the
two PDXs using IHC staining for ki-67 and cleaved caspase-3, respectively. We observed a
dramatic reduction in ki-67+ nuclei in both YLR074 and YLR102 shortly following osimertinib
treatment, which remained at a low level in residual tumors (Figure 2.2A-B), indicating that cell
cycle progression is inhibited in residual tumor cells. Cleaved caspase-3 staining was induced at
the beginning of TKI treatment and then returned to low baseline levels in residual disease
(Figure 2.2C-D), suggesting that apoptosis triggered by EGFR inhibition subsided in drug
tolerant tumor cells. Additionally, Western blotting of lysates obtained from untreated and
residual tumors from YLR074 and YLR102 PDXs revealed effective suppression of EGFR
phosphorylation indicating that tumor cell persistence was not due to incomplete activity of
osimertinib in these tumor cells (Figure 2.2E-F).
To investigate whether the residual state was reversible, we withdrew osimertinib in 2 mice
for each PDX line after 4 weeks (for YLR102) or 6 weeks (for YLR074) of osimertinib treatment
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at the time when residual disease was present (Figure S2.2A). Following osimertinib
withdrawal, the tumors grew out in the absence of osimertinib with a 3 to 10-fold increase in
tumor volume after 2-3 weeks off drug (Figure S2.2A-C) and the relapsed tumors retained
histological features characteristic of each PDX line (Figure S2.2D). Relapsed tumors continued
to produce the EGFR DEL19 mutant as determined by IHC (Figure S2.2D).
Together these results indicate that drug-tolerant residual tumor cells are characterized by
reduced proliferation and low levels of apoptosis, consistent with previous studies in human lung
cancer cell lines [44, 46, 57].

The clonal and mutational landscape of osimertinib-tolerant disease was similar to that
of untreated tumors.
To investigate the mechanisms that account for the presence of residual disease in the
PDXs, we first examined whether resistance-conferring mutations were present in the residual
tumor cells compared to the pre-treatment specimens. Resistance-conferring mutations may
pre-exist at a low frequency in treatment-naïve tumors and become clonally dominant during the
process of drug treatment. Supporting this possible scenario, in the context of mutant EGFR
lung cancers treated with first-gen EGFR TKIs, in some cases, the T790M mutation has been
observed in pre-treatment patient tumor specimens and parental cell lines [50, 58-60]. To
determine whether potential resistance-conferring mutations could account for drug tolerance,
we performed whole-exome sequencing (WES) on untreated and residual tumors and
compared sequencing results between the two conditions for each PDX line. We identified 242
non-synonymous mutations in YLR074 and 194 non-synonymous mutations in YLR102 through
this analysis. All of the mutations were present in both untreated and residual tumor cells,
without loss or gain of any mutation following 6 weeks of osimertinib treatment.
We also compared the variant allele frequencies (VAF) for the mutations in untreated and
residual disease samples and found that these were largely unchanged after osimertinib

18

treatment (Figure 2.3A-B) suggesting the absence of selection of specific mutations by drug
treatment. Consistent with this, pyrosequencing to confirm the allele frequency of the two
disease-related EGFR mutations (the exon19 deletion and T790M mutations) revealed that the
abundance of the EGFR mutations remained constant between untreated and residual disease
and that the VAFs were comparable with WES (Figure 2.3A-C). To add statistical power to our
observations, we performed a Fisher’s Exact Test to compare the VAF for every nonsynonymous mutation we identified in the two PDXs through WES. The majority of the
mutations were not statistically significantly different (Figure S2.3) and for the small number of
mutations that passed the test (7 in YLR074 and 11 in YLR102), we went on to determine
whether these mutations affected the clonal architecture using the clonal analysis program
PyClone [61]. As predicted by this program, the mutations were classified into different clusters
based on the relative abundance of the mutations in the whole cell population and the cellular
prevalence of each cluster did not change after osimertinib treatment in either of the PDXs,
which suggests that development of drug tolerance did not alter the clonal architecture of the
mutations in these mutant EGFR lung cancer PDXs (Figure 2.3D-E). The results of PyClone,
together with the VAF analysis for the mutations identified in pre- and post-treatment PDXs,
indicate that there is no specific genetic alteration being selected for or against during
osimertinib treatment and the mutational landscape remains very similar between untreated
tumor and residual disease.

Persistent tumor cells exhibited dramatic changes in transcriptional profiles compared to
untreated tumor cells.
Having excluded genetic alterations as major contributors to the drug tolerant phenotype in
our samples, we then turned to determine whether transcriptomic changes were present
between the untreated and residual tumor using bulk RNA-sequencing. Alignment results
showed that the majority of the sequencing reads were uniquely mapped to the human genome,
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for all of the samples submitted for RNA-sequencing, indicating that samples were mostly
composed of human tumor cells (Figure S2.4). Principal component analysis (PCA) of the data
showed a clear demarcation between the PDXs from each patient, irrespective of treatment,
indicating that features of the individual tumors dominate the transcriptional profiles. These data
also revealed that YLR102 residual disease was transcriptionally very different from YLR102
untreated tumor while YLR074 untreated and residual disease had more similar transcriptional
profiles (Figure 2.3F).
To identify pathways that were altered in the drug-tolerant disease in the PDXs, we
performed pathway analysis using MetaCore and found deregulation of genes in developmentassociated pathways including Wnt- and Hedgehog-signaling pathways in both PDXs (Figure
S2.5A), which are able to promote survival of tumor cells during drug treatment [62-65]. The
WNT pathway, specifically, has been shown to be enriched in residual disease specimens from
patients with EGFR mutant lung cancer after TKI therapy and this is likely related to the
activation of cell renewal and injury repair program [48]. A Hypoxia-Inducible Factor-1alpha
(HIF1α) regulated transcriptional program was the top downregulated pathway in both PDXs
following osimertinib treatment, which is probably a consequence of tumor shrinkage and
reduced hypoxia in tumor microenvironment due to increased access to oxygen (Figure S2.5A).
This is in line with the low-oxygen environment identified within PDX tumors, especially when
they reach a relatively big size [66, 67]. Consistent with the decreased Ki-67 staining in residual
disease, another prominent feature with residual PDX tumors is negative enrichment of cell
cycle pathways, indicating suppression of cell cycle progression and supporting the hypothesis
that tumor cells can survive treatment-induced pressure by exiting the cell cycle and entering a
dormant state [68] (Figure S2.5A-B).
Recent gene expression profiling of TKI-treated mutant EGFR lung cancer patient
specimens revealed upregulation of a gene expression signature representative of normal
alveolar cells [48]. In light of these findings, we examined the levels of expression of markers for
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different lung epithelial cell types in our RNA-seq datasets [69]. Although the alveolar gene
signature did not show significant enrichment in residual tumor cells in either of our PDX models
(Figure S2.5C), the expression of specific genes in the list exhibited a constant increase in
persister cells from both PDXs, including lung epithelial lineage factor Nkx2-1 and Aquaporin-4
(Table 2.1). Furthermore, both PDXs are characterized with upregulation of club cell marker
SCGB3A2 and downregulation of goblet and mucous cell marker MUC5B (Figure S2.5D). The
results of gene expression profiling for untreated and residual PDX tumors suggest that drug
tolerant residual disease represent a transcriptional state that differ from pre-treatment tumors
and might undergo a phenotypic change following TKI treatment.
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Figure 2.1 PDXs of mutant EGFR lung cancer showed incomplete responses to osimertinib
treatment. (A) Experimental design. (B) Basic information of the PDXs used in this study. (C-E) Tumor
growth curves showing normalized tumor size of each mouse bearing (C) YLR074, (D) YLR102 or (E)
YLR135 PDX following osimertinib treatment. Three biological replicates were included for each PDX
line. (F-H) Histological features of the PDXs before and after treatment, as indicated by (F) H&E
staining and IHC staining for (G) Nkx2-1 and (H) EGFR del19 mutant. Scale bar: 100μm.
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Figure 2.2 Drug tolerant residual tumors exhibited low level of proliferation and apoptosis. (AB) IHC staining for Ki-67 in untreated, short-term (3 days) treated and residual (6 weeks) tumors of
YLR074 and YLR102. Quantification of Ki-67 staining is shown in (B). Scale bar: 100μm. (C-D) IHC
staining for cleaved caspase-3 in untreated, short-term treated and residual tumors of YLR074 and
YLR102. Quantification of cleaved caspase-3 staining is shown in (D). Scale bar: 50μm. Significance
for IHC staining was determined by unpaired t-test between untreated and residual groups. Each
group contains six different fields of view. n.s.: p>0.05; ****: p<0.0001. (E-F) Immunoblotting for
phospho-EGFR and total EGFR in untreated and residual tumors in (E) YLR074 and (F) YLR102.
Each lane represents protein lysates from an individual tumor.
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Figure 2.3 Drug tolerant residual disease
showed minimal changes in mutational
landscape but dramatic changes in gene
expression profile compared to untreated
tumors. (A-B) Dot plots comparing variant allele
frequency of non-synonymous mutations
identified by WES between untreated and
residual tumors in (A) YLR074 and (B) YLR102.
Each dot represents one non-synonymous
mutation and disease-related EGFR mutations
are highlighted in black. The blue dashed line
running diagonally indicates where VAF of a
certain mutation in residual disease is equal to
that in untreated tumor. (C) Pyrosequencing for
EGFR del19 and T790M mutations in untreated
and residual tumors of YLR074 and YLR102.
Significance was determined by multiple t-test.
n=2 biological replicates for untreated group and
n=3 biological replicates for residual group. n.s.:
p>0.05. (D-E) Changes in clonality of mutations
identified in (D) YLR074 and (E) YLR102 after
osimertinib treatment, as predicted by PyClone
program. The mutations were separated into
multiple clusters and the number of mutations in
each cluster is indicated within the brackets. (F)
PCA plot visualizing the difference in gene
expression profiles between untreated and
residual tumors for YLR074 and YLR102.
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DISCUSSION
Incomplete response to drug treatment is almost inevitable in human cancer. For every
therapy given to patients, whether it is radiotherapy, traditional chemotherapy or targeted
therapy, tumor cells cannot be fully eradicated in most of the cases. During the clinical course,
the tumor burden usually stays stable in the presence of treatment, followed by progression in
either primary or metastatic sites upon acquired resistance. The biology of drug tolerant residual
disease in mutant EGFR-driven lung cancer has mainly been learned from in vitro research on
human cell lines and more recently from primary patient biopsies [40, 41, 48]. Appropriate
models are required to gain deeper insights into the mechanisms of drug tolerance in human
tumors. Patient specimens, depending on the sampling approach, are usually limited and
contain only a small number of tumor cells. Expanding tumor cells in a robust system is thus
critical to obtain sufficient materials for multitudinal profiling. We chose to grow patient tumor
tissues as PDXs in immunodeficient mice given that this model can retain both biological and
clinical traits of the original human samples [51, 52]. Indeed, PDX mouse models have been
used to model drug tolerance and acquired resistance in melanoma and successfully mimic the
treatment outcomes of targeted therapy in patients [70]. In the PDXs that we interrogated in this
thesis research, they exhibited a histology of aggressive adenocarcinoma, harbored the driver
mutations and maintained the TKI sensitivity, which are all characteristic of the patient tumors
that they were derived from. Two out of the three models also showed incomplete responses to
third-gen TKI osimertinib, providing opportunity to study drug tolerant residual disease in a more
clinically-relevant setting.
Despite the similarity between PDXs and human tumors, as an in vivo model, PDXs are not
perfect for detailed mechanistic studies such as genetic manipulation, CRISPR screening and
subsequent functional experiments. To address the questions related to molecular mechanisms,
ongoing work is focused on growing cancer cells as 2D or 3D cultures that can be geneticallymodified and assayed more easily.
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Cellular profiling of persistent tumor cells revealed that most of them entered a quiescent G0
stage as manifested by Ki-67 negativity and low level of apoptosis, which is consistent with cell
cycle-arrested DTPs identified in human cell lines [44]. The non-proliferative cell state is able to
protect malignant cells from cancer treatments, which preferentially target the fast-dividing cell
population. This quiescent state shares a great extent of similarity in biological features with
dormant tumor cells and in both scenarios cells are insensitive and refractory to treatment [68].
However, detailed molecular profiling suggests that DTP is likely a heterogeneous cell
population. Recent single-cell analysis of persister cells from human EGFR mutant lung cancer
cell lines revealed a DTP subpopulation that was not cell cycle arrested, which may contribute
to the eventual tumor cell regrowth [54]. In line with the in vitro study, most up-to-date study on
a new PDX sample in our cohort (data not shown) suggests that residual disease consisted of a
large number of Ki-67+ cells, indicating the possibility that depending on the tumor intrinsic
features drug tolerant cells can be cell cycle-active rather than quiescent.
Secondary drug resistant mutations in EGFR are major contributors to the mechanisms of
acquired resistance to all the EGFR TKIs that have been approved so far. These resistant cells
can arise either de novo or through selection of pre-existing mutation-positive subpopulation
[50]. In order to understand the mutational landscape of residual tumor cells, which are prelude
to relapse tumors, we performed WES to identify any resistance-conferring mutations that were
enriched in osimertinib-tolerant cells compared to untreated tumors. We did not observe ontarget EGFR mutations such as C797S and L718V/Q that are known to cause osimertinib
resistance in either untreated or residual tumor cells [23, 26, 27], nor any activating mutations in
KRAS that can bypass EGFR pathway [5, 23]. Furthermore, the allelic frequency and clonal
architecture of all the non-synonymous mutations identified through WES remained quite similar
between untreated cells and DTPs in the PDX models. The analyses of mutational status in the
PDXs before and after treatment suggest that pre-existing drug resistant mutations may not
contribute to the TKI tolerance in the PDX cohort that we examined. This is consistent with other
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studies indicating that the transcriptional landscape is the major difference between untreated
and residual disease.
Inter-tumoral heterogeneity is common in cancer patients. Tumors that are categorized in
the same histological subtypes and harbor the same oncogenic driver mutations may still exhibit
great extent of transcriptional difference due to genetic and epigenetic distinctions. The two
PDXs profiled in this chapter showed clear difference in gene expression when not treated with
TKI and osimertinib induced transcriptomic changes to different extent in different PDXs, as
revealed by RNA-seq. How this transcriptional discrepancy between patients determines
responses and tolerance to EGFR-targeted therapy is still not well understood. As discussed in
the next chapter, this transcriptional heterogeneity is not limited to PDXs and can be extended
to human lung cancer cell lines derived from different patients and the cellular contexts can
affect the role of certain genes in driving TKI tolerance. To investigate drug tolerant mechanisms
more comprehensively and understand the heterogeneity between patients, ongoing work is
focused on characterizing additional patient-derived models and synthesizing information
obtained from different sources.

EXPERIMENTAL PROCEDURES
Establishing PDXs in immune-deficient mice.
Immune-deficient NSG mice were purchased from The Jackson Laboratory. Mouse handling
and in vivo experiments were performed following the protocol approved by Institutional Animal
Care and Use Committee at Yale University.
Fresh or fresh-frozen tumor tissues were processed with tumor dissociation kit (Miltenyi
Biotech, 130-095-929) to generate single cell suspension. Cells were spun down and
resuspended in Matrigel (Corning, 356237), followed by subcutaneous injection into the flanks
of NSG mice. Materials equal to 100mm3 tumor tissues were injected into each mouse. Tumors
were let to grow freely until they reached desirable volume for further studies.
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Drug treatment in vivo.
Tumor-bearing mice were treated with osimertinib at 25mg/kg for five consecutive days each
week when their tumor size reached around 300mm3. The treatment lasted for 6 weeks before
drug tolerant residual tumor was excised, unless stated otherwise. Tumor burden was
measured by caliper once or twice per week.
Osimertinib (kindly provided by AstraZeneca) was dissolved in 0.5% methylcellulose
(Sigma-Aldrich, M0512) at 5mg/ml, with overnight stirring.

Immunohistochemistry staining.
Tumor tissues were fixed in 4% paraformaldehyde (Electron Microscopy Services, 15714-S)
and embedded in paraffin. FFPE tissue sections were deparaffinized in Clear-Rite 3 (Thermo
Scientific, 6901) and then rehydrated in serially diluted ethanol before heat-induced epitope
retrieval in antigen unmasking solution (Vector Laboratories, H-3300). The tissue sections were
then treated with 3% hydrogen peroxide (J.T.Baker, 2186-01) to remove endogenous reactive
oxygen species and blocked with goat serum (provided by VECTASTAIN Elite ABC-HRP kit,
PK-6101), followed by incubation with primary antibody at 4 degree overnight. The sections
were treated following the protocol in VECTASTAIN kit, stained with NovaRED substrate kit
(Vector Laboratories, SK-4800) and counterstained with hematoxylin (Vector Laboratories, H3401). Finally, sections were dehydrated and mounted in Permount (Fisher Scientific, SP15100).
Primary antibodies used for IHC: Nkx2-1 (abcam, ab76013, 1:250), EGFRdel19 (CST, 2085,
1:200).

Western blotting.
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Tissue powder or cells were lysed in RIPA buffer to extract proteins [39]. The protein
concentration was quantified using DC protein assay (Bio-Rad, 5000116), followed by protein
denaturation in 4X sample buffer (Bio-Rad, 1610747) supplied with 40mM DTT (Sigma-Aldrich,
D9779). Proteins of equal amount for each sample were loaded onto a 4-20% SDS-PAGE gel
(Bio-Rad, 4568093) and electrophoresis was performed at constant voltage until protein ladder
(Bio-Rad, 1610375) was well-separated. Proteins were then transferred to nitrocellulose
membrane (Bio-Rad, 1620112) and blocked in 5% non-fat dry milk (AmericanBio, AB1010901000). Blots were incubated with primary antibody at 4 degree overnight with constant shaking.
The membranes were then washed in TBS (Bio-Rad, 1706435) with 0.1% Tween-20 (SigmaAldrich, P7949), incubated with secondary antibody (CST, 7074, 1:2000) at room temperature
for 1 hour and washed again in TBST. The blots were developed using SuperSignal West Pico
(Thermo Scientific, 34580) or Femto (Thermo Scientific, 34096) chemiluminescent substrate
and chemiluminescence was detected in ChemiDoc MP gel imaging system (Bio-Rad).
Primary antibodies used for western blotting: pEGFR (CST, 3777), EGFR (CST, 4267),
EGFRdel19 (CST, 2085), Actin (Santa Cruz, sc47778 HRP, 1:2000). All the primary antibodies
were diluted in 5% non-fat dry milk by 1:1000, unless stated otherwise.

Whole exome sequencing.
PDX tumors were harvested and flash-frozen in liquid nitrogen. Frozen tissues were ground
into powder with mortar and pestle on top of dry ice. Genomic DNA was extracted from tissue
powder using AllPrep DNA/RNA mini kit (Qiagen, 80204). Genomic DNA quality is determined
by estimating the A260/A280 and A260/A230 ratios by nanodrop, both of which should be > 1.8,
and by 1% agarose gel electrophoresis. High quality DNA will migrate as a single high
molecular weight band. DNA samples were fragmented, ligated to adaptors and barcoded,
followed by exome target capture with xGen Exome Panel (IDT). The libraries were sequenced
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on illumina HiSeq4000 sequencer at Yale Center for Genome Analysis (YCGA) using 100bp
pair-end sequencing to generate data with 200X coverage per sample.

Bulk RNA-sequencing.
RNA was extracted from tissue powder or cell lines using AllPrep DNA/RNA mini kit. RNA
integrity was determined by running an Agilent Bioanalyzer gel, which measures the ratio of the
ribosomal peaks. Samples with RIN values of 7 or greater proceeded to library prep. RNA-seq
libraries were constructed using KAPA mRNA HyperPrep Kit (Kapa Biosystems, KR1352) and
sequenced on illumina HiSeq2500 sequencer using 75bp single-end sequencing to generate
around 30M reads per sample.

WES data analysis.
WES raw data were processed and analyzed with similar methods as described before [17].
In brief, Xenome [71] was used to classify the origin of sequencing reads and filter out the reads
originated from mouse. The remaining sequencing reads were aligned to the reference genome
(hg19) using BWA-MEM [72] followed by GATK Best Practices workflow [73]. Somatic
mutations were identified using MuTect2 [74] and Pisces [75] and in-house scripts were used to
filter out potential false positives. Likely damaging variants were annotated including premature
termination, canonical splice site, frameshift insertion/deletion, and missense mutation using
Annovar [76]. All somatic mutations were manually confirmed by visualizing read plots.

Estimation of tumor clonal population structure.
PyClone [61] was used to infer the subclonality in tumor samples. The software was
implemented to cluster somatic mutations incorporating the variant allele frequencies obtained
by MuTect2, using the hierarchical Bayes statistical model and the cellular prevalence of
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somatic mutations is estimated from a Dirichlet Process. Clusters containing at least 2
mutations and a mean of VAF greater than 5% were used.

RNA-seq data analysis.
RNA-seq raw data generated from PDXs were processed with BMX-seq pipeline as
described before [77]. In brief, sequencing reads were trimmed of adaptor sequences using
Trim Galore and mapped to a combined human (hg38) and mouse (mm10) genome using
STAR [78] to separate the components of the two species and to a combined transcriptome
(GENCODE v24 for human, vM10 for mouse) to add gene annotation. Then the uniquely
mapped reads were counted per annotation using featureCounts [79]. Finally, the counting
matrix went through DESeq2 package [80] to identify the genes that are differentially expressed
between different conditions.

Pathway enrichment analysis.
DEG lists with log2FoldChange and p-value for individua genes were used as input for
MetaCore software (https://portal.genego.com/). Enrichment analyses were performed only for
genes with log2FC>1 or <-1 and p-value<0.05, unless stated otherwise.

Gene Set Enrichment Analysis.
Differentially expressed genes identified in bulk RNA-seq were sorted and ranked by their
Wald statistic value as calculated by DESeq2 pipeline. Pre-ranked gene list was analyzed
against proper gene signatures through the GSEA software 3.0 downloaded from GSEA
website (https://www.gsea-msigdb.org/gsea/index.jsp) [81, 82]. Alveolar gene signature was
obtained from previous studies [48]. Cell cycle-related gene signatures were downloaded from
GSEA website.
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Figure S2.1 Mutant EGFR lung cancer PDXs were resistant to erlotinib. (A-C) Tumor growth
curves showing normalized tumor size of each mouse bearing (A) YLR074, (B) YLR102 or (C)
YLR135 PDX following erlotinib treatment.
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Figure S2.2 Tumor cells were still viable after development of drug tolerance. (A) Experimental
schema of tumor relapse assay for YLR074 and YLR102. (B-C) Relapse tumor burden normalized to
residual disease for (B) YLR074 and (C) YLR102 after 2 and 3 weeks off drug, respectively. (D) H&E
staining and IHC staining for EGFR mutant on tissue sections from YLR074 and YLR102 relapse
tumors. Scale bar: 100μm.
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Figure S2.3 The changes in VAF after osimertinib treatment remained statistically insignificant
for the majority of the non-synonymous mutations identified by WES. (A-B) Dot plots depicting
VAF of the mutations in the two PDX lines, similar to what is shown in Figure 2.3A-B. The dots
highlighted in red represent the mutations that pass the Fisher’s Exact Test (p-value<0.05).
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Figure S2.4 Human tumor cells were major components of the PDX tumors. Bar plots showing
the proportion of bulk RNA-seq reads mapped to human (hg) or mouse (mm) genome with or without
assigned features for each single tumor sample of YLR074 or YLR102.
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Figure S2.5 Transcriptional
features of drug tolerant residual
cells from PDX models. (A) Results
of MetaCore pathway analysis
showing the pathways predicted to be
up- or down-regulated in residual
disease in both PDXs. DEGs were
filtered with threshold=1; p<0.05 (B)
Enrichment plots for two cell cyclerelated gene signatures analyzed in
residual vs untreated tumors. (C)
Enrichment plots for lung alveolar
gene signatures analyzed in residual
vs untreated tumors. (D) Expression
level of selected lung epithelial marker
genes in untreated and residual tumor
cells from the PDXs.
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YLR074

YLR102

Gene ID
Log2FC

p-adj

Log2FC

p-adj

NKX2-1

0.43

0.039

0.44

5.55E-06

AQP4

3.28

1.17E-33

6.08

6.47E-186

Table S2.1 Changes in the expression of selected lung alveolar signature genes in osimertinibtolerant cells vs untreated cells from both PDXs.
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SUMMARY
Histological transformation and lineage transition are well-described mechanisms of
acquired resistance to EGFR TKIs whereas detailed cellular and molecular profiling of drug
tolerant persister cells that precede these changes in relapsed tumors remain poorly delineated.
To gain deeper insights into the potential lineage plasticity and evolution of DTRCs, we further
investigated the gene expression profiles of untreated and residual tumor cells in PDXs as
discussed in last chapter. Through these analyses we found upregulation of the neuroendocrine
lineage transcription factor ASCL1 in one of the PDX models following osimertinib treatment.
ASCL1 expression was accompanied by an increase in the expression of its target genes in
residual cells. Single-cell RNA-seq revealed that this ASCL1-mediated transcriptional program
was enriched in a subpopulation of untreated tumor cells that shared similar transcriptomic
features with DTRCs, suggesting that persister cells may arise from the selection of pre-existing
TKI tolerant clones. Functional studies of ASCL1 in established human cell lines indicate that in
a specific cellular context ASCL1 was able to induce an EMT signature which likely mediated
drug tolerance.

INTRODUCTION
LUAD tumors harboring EGFR activating mutations are more sensitive and thus benefit
more from EGFR TKI therapy, however, acquired resistance inevitably occurs to all EGFR TKIs.
Despite the relatively thorough investigation of on-target EGFR resistance conferring mutations
and bypass pathway activation [21, 30], the biology and evolution process underlying another
resistance mechanism, such as phenotypic transformations of the tumors, are not well
understood. Mutant EGFR-driven lung adenocarcinoma cells that undergo either SCLC
transformation or EMT become less dependent on EGFR activity and lose sensitivity to EGFR
TKIs. Despite the active searching for therapeutic approaches to overcome or prevent these
mechanisms of acquired resistance [49, 83], chemotherapy is still the most common therapeutic
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option for patients. This lineage plasticity that can lead to phenotypic transformation is not
limited in EGFR mutant lung cancer and has been identified in LUAD treated with other targeted
therapies (e.g. ALK inhibitor) or immune checkpoint inhibitors and other types of cancer as well
[84-87]. For example, in prostate cancer patients receiving anti-androgen therapy,
adenocarcinoma cells can undergo neuroendocrine differentiation giving rise to an aggressive
and drug-resistant cancer [87]. Besides trans-differentiation into neuroendocrine lineage,
squamous cell carcinoma transformation has also been identified in lung cancer patients
receiving first-line osimertinib [88]. This commonality across various clinical settings clearly
indicates the existence of mechanisms to overcome the lineage barrier between
adenocarcinoma and neuroendocrine cancer or squamous cell carcinoma under the selective
pressure of targeted and other therapies. However, little is known about the determinants of
lineage transition in that patient subset and how it develops in a stepwise manner. Drug tolerant
residual disease, as an intermediate stage, is a critical step during the development of tumor
relapse and the studies of its biology pave the way for understanding the lineage plasticity and
heterogeneity of cancer cells and identification of potential therapeutic vulnerabilities.
This chapter is focused on the context-dependent role of NE lineage factor ASCL1 in driving
TKI tolerance and promoting an EMT signature in mutant EGFR lung cancer. ASCL1 encodes a
basic helix-loop-helix transcription factor, which plays a central role in both physiological and
pathological processes, including the development of lung neuroendocrine cells and initiating
small cell lung cancer in both humans and genetically-engineered mouse models [89-92].
Approximately 8% of lung adenocarcinomas are also positive for ASCL1 and define a subset of
these tumors with neuroendocrine features [93]. Using single-cell RNA-sequencing, we
confirmed the presence of a population of persister-like cells that express ASCL1 signature
genes at a high level even before TKI treatment. Moreover, we demonstrate functionally that
ASCL1 led to drug tolerance in cells that were permissive to activation of an epithelial to
mesenchymal gene expression program. All the results that we obtained from different model
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systems suggest that ASCL1 may be a potential driver of tolerance to EGFR tyrosine kinase
inhibitors in mutant EGFR lung cancer.

RESULTS
An ASCL1-mediated transcriptional program was present in drug tolerant residual
disease.
The dramatic difference in the transcriptional profiles of untreated tumor vs. residual disease
in YLR102 (Figure 2.3F) raised the possibility that drug tolerance, in this case, could be due to
a population of cells with a new TKI resistant identity altogether. Further examination of
individual differentially expressed genes between residual disease and untreated tumor
revealed a dramatic upregulation of ASCL1 in YLR102 (but not in YLR074) (Figure 3.1A). This
was especially intriguing because ASCL1 is a neuroendocrine (NE) lineage transcription factor
that is highly expressed in one of the molecular subtypes of SCLC [94]. Since SCLC
transformation is one of the mechanisms of resistance to TKI therapies in mutant EGFR lung
cancer [29], ASCL1 upregulation in response to osimertinib treatment could be associated with
the neuroendocrine differentiation of these tumors. Moreover, ASCL1 has been shown to be a
pioneer factor given its ability to reprogram fibroblasts to neuronal cells [95].
To further confirm these observations, we examined expression of several canonical ASCL1
downstream targets including BCL2, DLL3, PROM1 and RET [92, 93]. All of these targets were
among the top upregulated genes in YLR102 residual disease (Figure 3.1B-E), and the
changes were retained at the protein level (Figure 3.1F). Indeed, while phosphorylation of
EGFR was effectively suppressed in the residual tumor, ASCL1 and its downstream targets
were all abundantly produced while they were undetectable by immunoblotting in the bulk
untreated tumor. Gene set enrichment analysis (GSEA) revealed that two previously published
ASCL1 gene signatures [92, 93] were positively enriched in YLR102 residual tumor cells
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(Figure 3.1G). Together these data indicate the presence of an ASCL1-mediated transcriptional
program in the residual disease from the YLR102 PDX.
Next, given the role that ASCL1 plays in the establishment of a neuroendocrine program we
investigated whether the YLR102 residual disease exhibited features of neuroendocrine
differentiation. In this regard, YLR102 residual disease retained histological features of lung
adenocarcinoma (Figure 2.1F) and did not show a dramatic increase in classical
neuroendocrine markers such as Synaptophysin, Chromogranin A and INSM1 (Figure S3.1).
Collectively, these data suggest that an ASCL1-mediated transcriptional program is
enriched in TKI-tolerant residual disease of EGFR mutant lung cancer despite no evidence in
neuroendocrine differentiation.

Rare ASCL1-high tumor cells pre-existing in untreated tumors were selected for upon
osimertinib treatment.
Drug tolerant residual cells can emerge through the selection of a rare drug-tolerant
population of cells present in the bulk tumor. Alternatively, treatment-induced changes in a
subset of cancer cells could lead to drug tolerance. To determine the origin of the drug-tolerant
ASCL1+ positive cells, we stained untreated and residual tumors for ASCL1. ASCL1 showed
clear nuclear staining in YLR102 residual tumor samples, which was consistent with its role as a
transcription factor (Figure 3.2A-B). ASCL1+ cells were present, but sparse, in untreated tumor
samples, as evidenced by immunohistochemistry (Figure 3.2A-B). This led us to hypothesize
that a small number of ASCL1hi tumor cells pre-existed in untreated tumors and got selected for
by osimertinib treatment. To validate this hypothesis, we used single-cell RNA sequencing to
determine whether we could identify a rare drug tolerant cell population in the untreated tumor.
Live EpCAM+ cells were sorted from a dissociated tumor cell suspension to specifically
enrich for human tumor cells (Figure S3.2A) since isolated EpCAM+ cells expressed mutant
EGFR (Figure S3.2B) and the EPCAM gene is expressed in both untreated and residual
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tumors, as shown by RNA-sequencing (Figure S3.2C). After processing of raw data, we
identified 5663 untreated cells and 1168 residual cells that would be incorporated into the
following analyses. Consistent with findings from our bulk RNA-seq data (Figure 2.3F), the
clustering results show a clear separation between untreated and residual cells (Figure 3.2CD). We also identified a small group of untreated cells that clustered together with residual
tumor cells in cluster 2 (Figure 3.2C-D and H), underscoring the transcriptional similarity
between these two cell populations in this specific cluster, whereas the majority of untreated
cells clustered separately from residual cells in the UMAP plot.
Similar to bulk RNA-seq findings, ASCL1, BCL2 and RET were more highly expressed in
drug tolerant residual cells (DTRCs) compared with untreated tumor cells (Figure 3.1A-E and
3.2E-G). The subpopulation of untreated tumor cells that clustered with DTRCs also showed
enrichment of ASCL1 and its target genes (Figure 3.2I) providing further evidence that ASCL1
positive DTRC-like tumor cells pre-exist in the untreated tumors and are selected for during
treatment with osimertinib. To examine whether selection of a pre-existing DTRC-like
subpopulation was unique to the YLR102 PDX we also performed single cell analysis of
untreated and residual cells from the YLR074 PDX and found that clusters 6 and 12 were
composed of cells from both conditions, indicating that cells transcriptionally resembling DTRCs
were also present in untreated YLR074 tumors, even though ASCL1 was not the driver of TKI
tolerance in this PDX line (Figure S3.3). These data indicate the presence of a population of
untreated tumor cells having properties of DTRCs which upon osimertinib treatment survive and
become the main cell population present in residual tumors.

ASCL1 triggered epithelial-to-mesenchymal transition (EMT) which was the likely
mediator of drug tolerance.
To investigate if and how ASCL1 causes drug tolerance, we turned to human mutant EGFR
lung adenocarcinoma cell lines for mechanistic studies. We used doxycycline-inducible vectors
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to express ASCL1 in HCC827, PC9 and H1975 cells and evaluated the impact of ASCL1 on
colony formation and viability in the presence of osimertinib (Figure 3.3A and S3.4A-B). In
HCC827 cells transfected with the empty vector (HCC827-EV), osimertinib eradicated colonies.
In contrast, in ASCL1-transfected cells (HCC827-ASCL1), the colony size was reduced by
osimertinib but a significantly higher number of colonies survived treatment (Figure 3.3B-C).
Further, HCC827-ASCL1 cells also showed a decrease in osimertinib sensitivity compared to
EV cells, as evidenced by a shift of the dose-response curve in a growth inhibition assay
(Figure 3.3D). The differential behavior of HCC827-EV and -ASCL1 cells when treated with
osimertinib indicate that ASCL1 promotes survival and drives drug tolerance in this cell line. In
PC9 and H1975 cells, ectopic ASCL1 expression did not affect the clonogenic activity of the
cells nor did it affect osimertinib sensitivity (Figure S3.4C-F). These data suggest that the ability
of ASCL1 to cause tolerance to EGFR TKIs depends on the cellular context.
To gain mechanistic insights into ASCL1-mediated TKI tolerance and determine what
distinguishes cells that are permissive to the phenotypic changes driven by ASCL1 and those
that are not, we performed RNA-seq on HCC827 and PC9 cell lines transfected with the EV or
ASCL1 vectors in the absence of osimertinib (vehicle) or treated with osimertinib for 3 and 10
days to acquire short-term treated cells and drug tolerant persisters, respectively. Gene
expression profiling of the cell lines in different conditions indicated a more dramatic
transcriptional change in the untreated HCC827 cell line compared to PC9 cells upon ASCL1
overexpression as revealed through principal component analysis (Figure S3.5A). These
findings were consistent with the observation that ASCL1-transfected HCC827 cells exhibited
morphological changes including increased number of protrusion-like structures and growth in
individual cells rather than in clusters, which were not seen in PC9 cells (Figure 3.4A). Pathway
analyses performed on the RNA-seq data from the two cell lines using MetaCore indicated that
EMT was the top upregulated pathway in HCC827 cells following ASCL1 expression but it was
not enriched in PC9-ASCL1 cells (Table 3.1). Given the known association of EMT with TKI
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resistance and activation of the EMT program upon ASCL1 expression in HCC827 cells, we
decided to further investigate the relationship between ASCL1-mediated EMT and TKI
tolerance. We examined the expression of individual epithelial and mesenchymal markers in our
RNA-seq datasets. Although these markers did not change significantly in PC9-ASCL1 cells
versus EV cells, their expression was altered dramatically in HCC827 cells following ectopic
ASCL1 expression, with a significant downregulation of epithelial markers (E-cadherin and
Epcam) and upregulation of mesenchymal markers (N-cadherin and Vimentin), indicative of
EMT (Figure 3.4B and S3.5B). This notion was further supported by GSEA, which showed
positive enrichment of an EMT gene signature in HCC827-ASCL1 cells as compared to EV
cells, but not in PC9 cells (Figure 3.4C).
The EMT phenotype identified in ASCL1-transfected HCC827 cells was strengthened by TKI
treatment. As drug tolerance developed, HCC827-ASCL1 cells exhibited greater enrichment of
EMT features compared to untreated cells (Figure 3.4B-C and Table 3.1). In contrast to the
EMT-mediated drug tolerance in ASCL1-overexpressed cells, EV-transfected HCC827 cells did
not persist upon osimertinib treatment and lacked robust enrichment of EMT features (Figure
3.3B and 3.4B). Inspection for the upstream EMT-related transcription factors revealed that
ZEB family members shared a similar transcriptional pattern with mesenchymal lineage markers
after ASCL1 overexpression and osimertinib treatment, and such a pattern was largely missing
for SNAI and TWIST family members (Figure 3.4B and S3.5C). This suggests that the ASCL1induced EMT phenotype in HCC827 cell line may be mediated by ZEB family members.
We also checked the bulk RNA-seq datasets of the PDX samples for several EMT markers.
Consistent with the discoveries from cell lines, in YLR102 residual disease where we identified
ASCL1 upregulation, E-cadherin was downregulated and Vimentin was upregulated as drug
tolerance developed and such changes were not observed in the ASCL1-unrelated case
YLR074 (Figure S3.5D).
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Taken together, the results obtained both in vitro and in vivo suggest that ASCL1 is able to
drive tolerance to EGFR TKI in mutant EGFR lung cancer by triggering EMT program.

ASCL1 was expressed and drove neuroendocrine phenotype in a subset of TKI-resistant
EGFR mutant lung cancer with SCLC transformation.
ASCL1 has been implicated as a dominant molecular identifier and master regulator of NE
differentiation in a subgroup of primary SCLC [94] but little is known about the molecular
subtyping of mutant EGFR lung adenocarcinoma that transforms to SCLC upon TKI exposure.
In order to gain insights into the drug resistance mechanisms in a clinically-relevant setting, we
developed repeat biopsy program at Yale Cancer Center that allowed us to collect treatmentnaïve and TKI resistant tumor specimens from the same patients and use these samples for a
variety of applications including histological analysis, NGS, growing them as PDXs and cell lines
etc. We chose to analyze the specimens that showed SCLC transformation as mechanism of
acquired resistance to EGFR TKIs in our patient collection and characterized their genetics and
expression of neuroendocrine marker genes. Since RB1 and TP53 loss are the most common
genetic alterations identified in SCLC [96], we first examined the mutational status and copy
number changes of these two genes in the patient specimens where genetic profiling data are
available. Consistent with SCLC, both RB1 and TP53 were frequently mutated in SCLC
transformed EGFR mutant lung cancer as well (3 out of 4) (Figure 3.5A). Copy number variants
for the two genes were not commonly identified in most of the patient samples except for
YUL0125, which showed a copy number gain of RB1 (Figure 3.5B). YUL0125 harbors a
frameshift deletion in RB1 so the amplified gene copies are likely to still carry this deleterious
mutation given the role of RB1 as a tumor suppressor gene. Further detection of RB1 proteins in
tumor cells by IHC staining is required to validate the functional consequences of the genetic
alterations.
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As revealed by recent studies, SCLC can be divided into multiple molecular subgroups
based on the expression of signature transcriptional regulators including ASCL1, NEUROD1
POU2F3 and YAP1 [94]. We performed histological analyses on patient tumor samples that
underwent SCLC transformation (Figure 3.5C) and examined the expression pattern of three
molecular identifiers of SCLC (ASCL1, NEUROD1 and YAP1). Three out of five tumors
(YLR051, YUL0025 and YUL0125) exhibited positive staining for ASCL1 and one tumor
specimen (YLR035) showed weak positivity for NEUROD1 (Figure 3.5D-E). YAP1 only showed
focal staining in YLR051 and YLR035 and is thus unlikely to be the transcriptional regulator that
defines these cases (Figure 3.5F). YUL0003 is negative for all the three markers and the
regulator of NE program in this particular case requires further investigation. The heterogeneous
expression of these transcriptional regulators in SCLC transformed EGFR mutant lung cancer is
consistent with what is identified in SCLC in general, highlighting that the transcriptional
heterogeneity of SCLC is recapitulated in EGFR mutant tumors that transform to SCLC upon
TKI treatment.
ASCL1 is able to drive neuroendocrine differentiation and required for maintaining NE status
in NE-high SCLC [91, 92, 97, 98]. To characterize the NE features in ASCL1-positive SCLC
transformation cases, we examined the expression level of multiple NE markers in pretreatment and resistant YUL0025 tumor samples through bulk RNA-seq. We observed a
dramatic upregulation of ASCL1 and NE marker genes as the tumor cells acquired resistance to
EGFR TKI and transformed into SCLC (Table 3.2), indicating a neuroendocrine phenotype in
resistant tumor cells. The cellular and molecular profiling of the SCLC transformation cases
suggest that expression of SCLC molecular identifiers is heterogeneous, with a subgroup being
positive for ASCL1, which is correlated with a strong NE signature. The expression of
neuroendocrine lineage factor ASCL1 in TKI-tolerant residual disease might pave the way for
NE differentiation and lead to SCLC transformation and eventually acquired resistance.
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Figure 3.1 An ASCL1 gene expression program was specifically activated in YLR102 residual
tumor cells. (A-E) Expression level of ASCL1 and some of its target genes in untreated and residual
tumors of YLR102, as evidenced by bulk RNA-seq. Significance for gene expression changes was
determined by unpaired t-test between untreated and residual groups. n=2 biological replicates for
untreated group and n=3 biological replicates for residual group. n.s.: p>0.05; **: p<0.01; ***: p<0.001;
****: p<0.0001. (F) Immunoblotting to detect protein level of ASCL1 and its downstream targets. Each
lane represents protein lysates from an individual tumor. (G) GSEA results showing enrichment of two
ASCL1 gene signatures in residual tumor cells versus untreated ones.

48

49

Figure 3.2 ASCL1hi persister-like cells pre-existed in the YLR102 untreated tumor. (A) IHC
staining for ASCL1 on untreated and residual tumor sections of YLR102. Red arrow heads point to the
nuclei stained as positive. Scale bar: 100μm. (B) Quantification of ASCL1 staining in YLR102.
Significance for IHC staining quantification was determined by unpaired t-test between untreated and
residual groups. Each group contains six different fields of view. ****: p<0.0001. (C-D) UMAP plots
showing clustering of YLR102 untreated and residual tumor cells by single-cell RNA-sequencing. (EG) Feature plots depicting expression of ASCL1-related genes in individual cells. (H) Number of
untreated and residual tumor cells in each individual cluster. Cluster 2 is highlighted in red frame. (I)
Heatmap showing relative expression level of ASCL1 signature genes per cluster per condition.
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Figure 3.3 ASCL1 overexpression caused TKI tolerance in HCC827 cell line. (A) Immunoblotting
for ASCL1 in HCC827 cells transfected with empty vector or ASCL1 vector, upon doxycycline
treatment with dose escalation. (B) Clonogenic assay for HCC827-EV or -ASCL1 cells treated with
different concentrations of osimertinib for 10 days. (C) Quantification of colony number in (B).
Significance was determined by multiple t-test. n=3 technical replicates for each condition. **: p<0.01;
****: p<0.0001. (D) Drug sensitivity assay measuring readout of CellTiter Blue for HCC827-EV and ASCL1 cells when treated with osimertinib at different doses. n=4 technical replicates per condition.
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Figure 3.4 ASCL1 expression led to EMT phenotype in permissive cellular contexts. (A)
Morphology of PC9 and HCC827 cells transfected with EV or ASCL1. Scale bar: 100μm. (B)
Expression level of EMT marker genes in PC9 and HCC827 with or without ASCL1 overexpression,
treated with or without osimertinib. Significance was determined by unpaired t-test. n=3 technical
replicates for each condition. n.s.: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.
V=vehicle-treated; O=osimertinib-treated at 100nM for 3 days; P=persister after 10 days of osimertinib
treatment at 100nM. (C) GSEA results showing the enrichment of EMT gene signature in untreated
HCC827-ASCL1 cells compared to HCC827-EV cells; HCC827-ASCL1 persister cells compared to
untreated HCC827-ASCL1 cells; and untreated PC9-ASCL1 cells compared to PC9-EV cells.

53

Figure 3.5 TKI resistant EGFR-driven LUAD with SCLC transformation exhibited heterogeneous
expression of subtype-defining transcriptional regulators of SCLC. (A-B) Mutational and copy
number status RB1 and TP53 in SCLC transformation cases. (C-F) H&E staining (C) and IHC staining
for subtype-defining factors of SCLC including (D) ASCL1, (E) NEUROD1 and (F) YAP1. Scale bar:
100μm.
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DISCUSSION
Histological transformation such as SCLC transformation and EMT are well-established
mechanisms of TKI resistance and have been reliably observed in lung cancer patients
receiving EGFR TKIs. The factors that determine which subset of patients undergo this
phenotypic change and the detailed evolutionary process through which lineage transition is
developed remain poorly understood. Investigating the cellular and molecular features of drug
tolerant residual disease provides an opportunity to understand resistant mechanisms more
comprehensively. Through transcriptomic profiling of residual tumors in our PDX models, we
identified upregulation of ASCL1 in persistent tumor cells compared to untreated cells in one of
the PDXs. ASCL1 is an important regulator of NE differentiation in SCLC however NE markers
did not show enrichment in drug tolerant persister cells (Figure S3.1) and the residual tumor
retained histology of adenocarcinoma without NE features (Figure 2.1F), suggesting that
lineage transition did not occur in residual tumor cells despite increased expression of ASCL1.
Previous genetic analyses of EGFR mutant lung cancer with SCLC transformation revealed a
common RB1 loss, which is consistent with our patient cohort (Figure 3.5A). The expression of
RB1 appeared to be intact in YLR102 PDX in which ASCL1 upregulation was identified given
that it did not harbor any RB1 mutation and this gene was normally transcribed as indicated by
RNA-seq. Therefore, additional genetic or epigenetic alterations may be required to trigger
histological transformation. Ongoing work is focused on determining whether RB1 loss is
required for NE phenotype to be manifested through knockout of RB1 in PDX and cell lines of
mutant EGFR-driven lung cancer in the presence of ASCL1.
Through in vitro assays for TKI sensitivity, we determined the role of ASCL1 in driving
osimertinib tolerance in established human lung cancer cell lines. ASCL1 caused TKI tolerance
by inducing an EMT signature specifically in HCC827 but not in the other lines, suggesting that
cellular context can affect the lineage transforming function of ASCL1. Indeed, ASCL1 functions
as a pioneer transcription factor to reprogram various cell types into neuronal cells only in the
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presence of permissive epigenetic landscape [95]. Given the tendency of the HCC827 cell line
to undergo EMT upon resistance to osimertinib, the current working hypothesis is that the genes
encoding EMT-related regulators and markers are more accessible in this line compared to the
others. To determine the chromatin accessibility for EMT-related genes in the human LUAD cell
lines with or without ASCL1 overexpression, we are performing Assay for TransposaseAccessible Chromatin using sequencing (ATAC-seq) for HCC827 and PC9 cell lines in different
conditions to address the complexity of permissiveness underlying ASCL1-induced EMT.
Intratumoral heterogeneity plays a critical role in the development of acquired resistance to
targeted therapies. At the genetic level, subpopulations harboring resistance-conferring
mutations quickly adapt to drug treatment and becomes the dominant clone in relapse tumor
[50, 59, 60]. At transcriptional level, cells in a pre-existing drug tolerant state can survive
treatment and be enriched in residual disease, which further evolves into acquired resistance
[70]. In the mutant EGFR lung cancer PDXs that we examined in this study, transcriptional
changes appeared to be the major contributor to TKI tolerance and single cell RNA-seq
revealed pre-existing DTRC-like subclones, supporting the hypothesis of subclonal selection.
One question that remains to be answered is whether adaptation to osimertinib may have any
effect on the drug tolerant phenotypes. Despite the fact that the results of scRNA-seq clearly
support the hypothesis of selection, we cannot exclude that adaptive changes induced by
osimertinib may also be occurring and conferring drug tolerance. Future studies combining
intricate cell barcoding technology and NGS may facilitate the efforts to track down the cell fate
of individual clones and distinguish between the roles of selection and adaptation.

EXPERIMENTAL PROCEDURES
Cell lines.
All of the human lung adenocarcinoma cell lines (PC9, H1975 and HCC827) and 293T/17
cell line used in my thesis research were purchased from ATCC. The LUAD cell lines were
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cultured in RPMI 1640 medium (gibco, 11875-093) supplemented with 10% fetal bovine serum
(gibco, 16140-071), 1mM sodium pyruvate (gibco, 11360-070), 10mM HEPES (gibco, 15630080), 100U/ml penicillin and 100ug/ml streptomycin (gibco, 15140-122). 293T cells were
cultured in DMEM medium (gibco, 11965-092) supplemented 10% FBS, 1mM sodium pyruvate,
100U/ml penicillin and 100ug/ml streptomycin. Cells involved in doxycycline induction
experiments were cultured with tet system approved FBS (Takara Bio, 631101) instead. Cells
were frozen down in FBS plus 10% DMSO (AmericanBio, AB00435-00500) for preservation.

Immunohistochemistry staining.
Experimental details are the same as described in chapter 2.
Primary antibodies used for IHC: ASCL1 (abcam, ab211327, 1:500), NEUROD1 (abcam,
ab213725, 1:1000), YAP1 (CST, 14074, 1:400).

Western blotting.
Experimental details are the same as described in chapter 2.
Primary antibodies used for western blotting: ASCL1 (abcam, ab211327), BCL2 (CST,
4223), DLL3 (CST, 71804), RET (CST, 14556), Nkx2-1 (abcam, ab76013), EpCAM (abcam,
ab32392), Vimentin (CST, 5741). All the primary antibodies were diluted in 5% non-fat dry milk
by 1:1000, unless stated otherwise.

Bulk RNA-sequencing.
Experimental details are the same as described in chapter 2.

RNA-seq data analysis.
RNA-seq raw data generated from human cell lines were trimmed of adaptor sequences
using Trim Galore (v0.5.0, https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and
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mapped to the human reference genome (hg38) using HISAT2 [99]. The sequencing reads
were annotated according to GENCODE v27 model and gene expression levels were quantified
using StringTie [100]. Differentially expressed genes were identified using DESeq2 [80].

Pathway enrichment analysis.
Experimental details are the same as described in chapter 2.

Gene Set Enrichment Analysis.
Experimental details are the same as described in chapter 2. ASCL1 gene signatures were
obtained from previous studies [92, 93]. EMT gene signature was downloaded from GSEA
website.

Single-cell RNA-sequencing.
Subcutaneous PDX tumors were resected from mice and processed with tumor dissociation
kit. The single-cell suspension was stained with human EpCAM antibody (BioLegend, 324209,
1:100) and LIVE/DEAD cell stain (invitrogen, L34971, 1:250), and subjected to FACS to isolate
live tumor cells, based on the gating strategy shown in Figure S3.2A. The sorted cells were resuspended in FACS buffer and loaded on the Single Cell A Chip together with RT Master Mix
and barcoded gel beads to form nanoliter-scale Gel Beads in Emulsions (GEMs) through
Chromium Controller. The single-cell cDNA libraries were constructed using 3’ library prep kit v3
(10X genomics) and then sequenced on illumina HiSeq4000 sequencer using 100bp pair-end
sequencing to generate approximately 150M reads per sample.

Single-cell RNA-seq data analysis.
The single-cell sequencing raw data were processed and mapped to a human-mouse hybrid
genome to distinguish between human and mouse cells. Then gene expression matrix for
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human cells is generated by Cell Ranger pipeline and analyzed using Seurat package (v3.0) in
R language [101, 102]. Genes whose expression was identified in at least three cells would be
considered as features and cells with number of feature genes greater than 200 but smaller
than 7000 and percentage of mitochondria reads less than 50% were included in the following
analyses. The single-cell expression data were normalized by SCTransform embedded in
Seurat v3 and then underwent linear dimensional reduction through PCA. The first 100 principal
components were used to cluster cells, with a resolution of 0.4. The clustering results were
visualized with UMAP plot. Expression level of individual genes was visualized with feature plots
and heatmaps.

ASCL1 overexpression in human LUAD cell lines.
Human ASCL1 cDNA was amplified from phASCL1-N106 (addgene, #31781) with Q5 HF
master mix (NEB, M0492S), ASCL1_F and ASCL1_R, and purified with Monarch PCR & DNA
Cleanup Kit (NEB, T1030S). Cleavage sites for NheI (NEB, R3131S) and AgeI (NEB, R3552S)
were added to both ends during PCR. After digestion of the PCR products and pCW57-MCS
empty vector (addgene, #71782) with both restriction enzymes and purification of the digestion
products, ASCL1 cDNA insert was ligated to plasmid backbone using T4 DNA ligase (NEB,
M0202S). The ligation products were transfected into stbl3 competent E. coli (invitrogen,
C7373-03) and bacteria were spread on ampicillin LB agar plate. Single clones were cultured in
LB broth (gibco, 10855-021) with 100ug/ml ampicillin (AmericanBio, AB00115-00010) overnight
and plasmids were extracted by QIAprep spin miniprep kit (Qiagen, 27106). Successful ligation
was confirmed by sanger sequencing using the sequencing primer.
The pCW57-hASCL1 vector and empty vector were then packaged into lentivirus with
TransIT-Lenti reagent (Mirus Bio, MIR6604). Target vectors and two packaging plasmids –
pMD2.G (addgene, #12259) and psPAX2 (addgene, #12260) were transfected into 293T cells
following instructions of TransIT-Lenti. Lentivirus-containing cell medium was collected 2 days
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following transfection and ran through 0.45um filter (Millipore, SLHV033RS) to remove cell
debris. Lentivirus was concentrated through ultracentrifugation at 18000rpm, 4 degree for 2h
and resuspended with PBS. Lentiviral particles were added to cell medium one day after cell
seeding, supplemented with 8ug/ml TransduceIT reagent (Mirus Bio, MIR6620) to facilitate
infection. Lentivirus-infected cells were treated with puromycin (gibco, A11138-03) at
appropriate concentrations (0.7ug/ml for PC9 and 0.5ug/ml for H1975 and HCC827) for one
week to generate stable cell lines.
Cells transfected with EV or ASCL1 vector were maintained in RPMI 1640 cell medium
supplemented with 10% tet system-certified FBS and 1ug/ml doxycycline (Sigma-Aldrich,
D9891), unless stated otherwise.
Primers used in this section are listed here. ASCL1_F: 5’-AGCTAGCGCGGCCGCCACC-3’.
ASCL1_R: 5’-GACCGGTTCGCGATCTAGA-3’. Sequencing primer for pCW57-hASCL1: 5’CGTATGTCGAGGTAGGCGTG-3’.
All the plasmids were obtained from Addgene. phASCL1-N106 was a gift from Jerry
Crabtree (Addgene plasmid # 31781). pCW57-MCS1-2A-MCS2 was a gift from Adam Karpf
(Addgene plasmid # 71782). pMD2.G and psPAX2 were gifts from Didier Trono (Addgene
plasmid # 12259 and 12260).

Clonogenic assay.
Cells were seeded with doxycycline in 6-well plates and treated with drug vehicle or
Osimertinib at various concentrations for 10 days. Seeding density is 250 cells/well for H1975
EV/ASCL1 cells and 500 cells/well for the other cell lines. Cell medium containing drugs was
replenished every three days. Cell clones formed in the absence or presence of osimertinib
were fixed with 4% PFA and stained with crystal violet (Sigma-Aldrich, C3886). Tissue culture
plates were then washed with water to remove excess stain and dried for pictures and
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quantification. Osimertinib was dissolved in DMSO and final concentration of drug vehicle was
no more than 1:1000 in cell culture medium.

Drug sensitivity assay.
Cells were seeded with doxycycline in 96-well plates and treated with drug vehicle or
Osimertinib at escalating concentrations for 3 days. Seeding density is 3500 cells/well for PC9
EV/ASCL1 cells, 3000 cells/well for H1975 EV/ASCL1 cells, 3500 cells/well for HCC827 EV
cells and 2500 cells/well for HCC827 ASCL1 cells. Cell viability was determined with CellTiter
Blue reagent (Promega, G8081) following manufacturer’s protocol. Fluorescence was measured
with SpectraMax M3 plate reader.
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Figure S3.1 YLR102 residual disease did not show histological transformation into SCLC. The
table showed the RPKM value of individual NE marker genes and SCLC subtype identifiers in each of
the YLR102 samples as well as the log2-scaled fold change in gene expression in residual disease
group as compared with untreated group.
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Figure S3.2 Human tumor cells were enriched for single-cell RNA-sequencing by FACS. (A)
Experimental scheme. (B) Expression of lung epithelial markers in EpCAM+ and EpCAM- cells sorted
from YLR102 PDX. (C) Expression level of EPCAM in untreated and residual tumors of YLR102.
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Figure S3.3 DTRC-like tumor cells pre-existed in untreated YLR074 PDX. (A) UMAP plots showing
clustering of YLR074 untreated and residual tumor cells by single-cell RNA-sequencing. (B) Number of
untreated and residual tumor cells in each individual cluster. Cluster 6 and 12 are highlighted in red
frame.
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Figure S3.4 ASCL1 overexpression did not affect osimertinib sensitivity in PC9 or H1975 cell
lines. (A-B) Immunoblotting for ASCL1 in (A) PC9 and (B) H1975 cells transfected with empty vector
or ASCL1 vector, upon doxycycline treatment with dose escalation. (C-D) Clonogenic assay for EV or
ASCL1 transfected (C) PC9 and (D) H1975 cells treated with different concentrations of osimertinib for
10 days. (E-F) Drug sensitivity assay for (E) PC9-EV/ASCL1 and (F) H1975-EV/ASCL1 cells when
treated with osimertinib at different doses.
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Figure S3.5 ASCL1 expression led to EMT phenotype in permissive cellular contexts. (A) PCA
plot visualizing the gene expression profiles of different experimental groups. (B) Immunoblotting of
epithelial and mesenchymal markers in PC9 and HCC827 cell lines following ASCL1 overexpression.
(C) Expression level of SNAI and TWIST transcription factors in PC9 and HCC827 cells under different
experimental conditions. (D) Expression of epithelial and mesenchymal markers in untreated and
residual tumors in YLR074 and YLR102 revealed by RNA-seq. Significance was determined by
unpaired t-test. n=2 biological replicates for untreated group and n=3 biological replicates for residual
group. n.s.: p>0.05; *: p<0.05; ***: p<0.001.
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Table S3.1 Top 5 upregulated pathways in HCC827 and PC9 cells after ASCL1 overexpression
and osimertinib treatment as predicted by MetaCore software.
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Table S3.2 Expression level of NE markers and subtype-defining transcriptional regulators of
SCLC in pre- and post-TKI EGFR-driven lung cancer. The table showed the FPKM value of
individual NE marker genes and SCLC subtype identifiers in patient specimens obtained from pre-TKI
(YUL0025P) and TKI-resistant SCLC-transformed tumors (YUL0025R) from the same patient.
Expression levels of dramatically upregulated genes were highlighted in red for post-TKI tumor
sample.
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SUMMARY
PDX models serve as critical tools for understanding drug tolerant residual disease from a
clinical perspective given that these preserve a number of biological traits of patient specimens.
However, the lack of a functional immune system in an NSG mouse host results in a defective
interaction between tumor cells and the microenvironment. To gain more comprehensive
knowledge about TKI tolerance in an immunocompetent system, we performed complementary
research using a refined genetically-engineered mouse model (GEMM), in which lung tumor
cells are labeled with the fluorescent marker mKate to enable cell sorting. We characterized
multiple aspects of this model, including tumor development, histology, response to EGFR TKIs
and isolation of untreated and residual tumor cells. Gene expression profiling of mKate+ cells
sorted from tumor bearing mice with or without osimertinib treatment revealed common
pathways that are deregulated in both GEMM and PDX models.

INTRODUCTION
Cancer can be modeled both in vitro as 2D or 3D cultures and in vivo with tumors growing in
experimental animals. In chapter 2 and 3, we discussed our studies on drug tolerant residual
disease in PDX models, which provided insights into the mechanisms of drug tolerance in a
clinically-relevant setting. In order to reduce graft rejection and ensure successful engraftment
of human tumor tissues in a murine system, the mouse hosts are engineered to have a severe
immune deficiency [103, 104]. The lack of a functional immune system in PDXs means that
interactions between tumor cells and immune cells in the microenvironment are not
recapitulated in these models. Furthermore, in most PDX models, tumor cells are grown
subcutaneously rather than in the organs where patient biopsies were obtained. Therefore these
models do not fully represent tumor development and drug response in the most physiologicallyrelevant conditions. In order to gain comprehensive knowledge about mechanism of TKI

71

tolerance in EGFR mutant lung cancer, we performed complementary studies on the biology of
tumor cells in an immune-competent genetically-engineered mouse model.
Transgenic mice have been widely used to study the biology and drug resistance of EGFR
mutant lung adenocarcinoma [23, 53, 105]. Transgenes encoding oncogenic drivers are
integrated into the mouse genome and their expression is induced specifically in lung epithelial
cells using a doxycycline-inducible genetic approach, resulting in transformation of healthy lung
epithelial cells into lung adenocarcinoma cells. The mouse tumors therefore develop
orthotopically in the lungs in the presence of the lung microenvironment and tumor-bearing mice
can be used to study the biology of the tumors, therapeutic responses, drug resistance and,
importantly for this project, drug tolerant persister cells.
GEMMs have been successfully used to model acquired resistance to EGFR TKIs and
identify resistance mechanisms. In general, the tumor-bearing mice respond quite well in the
beginning of TKI treatment and the mouse lungs appeared to be normal through imaging and
histological analysis, however, TKI resistant tumor nodules develop after a prolonged and
continuous treatment [23, 106], indicating the presence of drug tolerant residual cells despite
the almost complete drug response.
In this chapter, we refined and characterized a GEMM of EGFR-driven lung cancer such that
cancer cells were labeled with the fluorescent protein mKate that enabled them to be sorted.
mKate+ cells isolated from untreated and treated mice can be genetically and transcriptionally
profiled to identify mechanisms of drug tolerance. Although tumor-bearing mice showed an
almost complete response to osimertinib, mKate+ cells were still present following TKI
treatment. Through targeted deep sequencing, we did not find any EGFR mutations in the
residual cells that are known to confer resistance. Comparison of the gene expression profile
between untreated and residual cells revealed some gene signatures that were shared between
residual diseases identified in PDX models and GEMM as well as features that were unique to
the transgenic mouse model.
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RESULTS
Identification and isolation of drug tolerant residual cells in a GEMM of EGFR mutant
lung cancer.
To induce the expression of mutant EGFR and label tumor cells with a fluorescent marker,
we crossed mice carrying a doxycycline-inducible mutant EGFR transgene with a conditional
allele that encodes the rtTA transcriptional activator and red fluorescent protein mKate that were
expressed upon deletion of a lox-stop-lox cassette by Cre recombinase [107]. A CreER
transgene was under control of Sftpc promoter, which enabled the expression of recombinase
specifically in type II alveolar lung epithelial cells in a tamoxifen inducible manner [108].
Additionally, a Trp53 floxed allele is incorporated into the model to accelerate tumor
development and increase the aggressiveness of tumor cells [109, 110]. Mice of the appropriate
genotype (Figure 4.1A-B) were administered tamoxifen to activate CreER recombinase, which
initiated rtTA and mKate expression and deleted Trp53 gene in lung epithelial cells. Mice were
then fed with a doxycycline diet to induce expression of the EGFR L858R mutant, which drove
transformation of healthy lung epithelial cells into lung adenocarcinoma cells. Theoretically, all
the cells that express mutated EGFR would be labeled with mKate and can be isolated through
FACS.
To verify tumor development, we monitored the tumor volume in mouse lungs by magnetic
resonance imaging (MRI). Typically, after 6-10 weeks on a DOX diet and initial tamoxifen
treatment, mice developed diffused tumor lesions in the lungs that were responsive to both the
first generation TKI erlotinib and third generation TKI osimertinib (Figure 4.1C-D and S4.1A-B).
The lung tumors regressed almost completely after treatment with osimertinib for 4 weeks and
the histology of the lungs of TKI-treated mice reverted from harboring lung adenocarcinomas to
looking histologically normal and similar to those in healthy mice (Figure 4.1E and S4.1C). In
contrast, tumor bearing mice only showed partial responses to erlotinib in most cases (Figure

73

S4.1C), indicating a more potent anti-tumor effect of osimertinib compared to erlotinib. Whether
this reflects a difference in the ability of the TKIs to inhibit EGFR in this model remains to be
determined.
One of the advantages of this transgenic mouse model is expression of fluorescent marker
in lung epithelial cells, including tumor cells. To validate expression of mKate and confirm the
presence of drug tolerant residual cells in mice with complete tumor regression, we probed for
mKate+ cells in mouse lungs before and after osimertinib treatment by IHC staining and FACS.
Pre-treatment tumor cells showed strong positivity for EGFR mutant and mKate (Figure 4.2A).
The mKate+ cells could also be detected by flow cytometry both before and after osimertinib
treatment (Figure 4.2B-C) despite the absence of sizable post-treatment tumor lesions as
revealed by MRI and histological analysis (Figure 4.1C-E). To determine the appropriate time
point to collect DTRCs, we treated tumor-bearing mice with osimertinib for 4 or 6 weeks until the
tumors were no longer visible and compared the number of mKate+ cells isolated from mouse
lungs between the two groups. There was no significant difference between the 4- and 6-week
groups, indicating that maximal tumor regression had been achieved by week 4 on drug (Figure
4.2B). Therefore, we collected mKate+ cells after 4 weeks of osimertinib treatment. Besides
mKate+ cells isolated from TKI-naïve and treated mice, we were also able to collect them from
healthy mice that do not harbor mutant EGFR transgene through sorting (Figure 4.2B and
4.3A). The cellular profiling of the lung tumors suggests that tumor cells still persist even after
they become undetectable by imaging and the DTRCs, although few in number, can be
collected through FACS.

Transcriptional profiling of the tumor cells isolated from the pre- and post-treatment
GEMM revealed pathways deregulated in DTRCs.
In order to identify the mechanisms that drive TKI tolerance in the GEMM, we sought to
investigate and compare the molecular features of untreated tumor cells and drug tolerant
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persisters. As GEMMs of mutant EGFR lung cancer are often used to study on-target
mechanisms of acquired resistance to EGFR TKIs [23, 106], our first step for this molecular
profiling was to search for mutations in EGFR that conferred resistance to first-, second- and
third-generation TKIs in pre- and post-treatment tumor cells isolated from the GEMM (Figure
4.3A). We performed targeted deep sequencing for the EGFR coding regions that covered the
codons that were known to be mutated and cause acquired resistance, including L718V/Q,
T790M and C797S [23-27]. We also examined the presence of the EGFR L858R mutation
encoded in the transgene as positive control to ensure proper sequencing and data analysis.
The common drug resistant EGFR mutations were not detected in treatment-naïve, osimertinibtreated or erlotinib-treated tumor cells whereas the L858R mutation was uniformly present
(Figure S4.2), suggesting that resistance conferring mutations in EGFR were not the major
contributors to the drug tolerant phenotypes in the TKI-treated GEMM.
Since on-target genetic mechanisms were not identified in post-osimertinib mKate+ cells, we
then went on to profile the transcriptomic changes in mKate+ cells after 4 weeks of osimertinib
treatment versus mKate+ cells prior to TKI treatment. We sorted mKate+ cells from TKI naïve
and long-term osimertinib treated (4 weeks) tumor bearing mice, as well as from healthy mice in
which lung epithelial cells were labeled with mKate but lacked mutant EGFR expression (Figure
4.3A). Bulk RNA-seq of mKate+ cells collected from healthy, untreated and osimertinib-treated
mice revealed dramatic differences in gene expression between the three groups (Figure 4.3B).
This result further indicates that mKate+ cells isolated from healthy mice and tumor bearing
lungs following complete response to osimertinib were not transcriptionally identical despite the
similar histology shared by healthy tissue and osimertinib treated lung tissue (Figure 4.1E). The
expression level of lung epithelial markers was largely retained across different conditions,
indicating the isolation of correct cell types through mKate sorting (Table 4.1). In order to
systematically analyze the gene expression profiles, we performed the MetaCore pathway
analysis for the bulk RNA-seq data of mKate+ cells to identify the pathways that were potentially
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altered in post- vs pre-treatment mKate+ cells. Such analyses revealed transcriptional programs
that were positively or negatively enriched in osimertinib-treated mKate+ cells compared to
untreated counterparts. Top pathways that were upregulated in post-treatment cells included a
lipid biosynthesis pathway mediated by SREBP and development-related NOTCH pathway. The
functional and mechanistic implications of these pathways remain to be studied in order to
address how they are related to TKI tolerance. The downregulated pathways in mKate+ cells
following osimertinib treatment were mainly centered in cell cycle and target genes of HIF-1α
(Figure 4.3C). It is worth noting that similar programs were also implicated in pathway analysis
for residual tumor cells in our PDX models, including upregulation of development-related
pathways such as Wnt signaling and Hedgehog signaling and downregulation of cell cyclerelated pathways and HIF-1α activity (Figure S2.5A-B). The commonality between GEMM and
PDX models suggests that signaling networks critical for normal growth and development may
be hijacked by residual tumor cells to promote survival and that treatment-induced cell cycle
arrest and reduced hypoxia due to tumor regression are hallmarks of residual disease.
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Figure 4.1 Tumor-bearing transgenic mice of mutant EGFR LUAD showed complete responses
to osimertinib. (A) Transgenic composition of the GEMM used for study of drug tolerance. (B)
Experimental schema for tumor development and TKI treatment. (C) Tumor burden in osimertinibtreated mice as measured by MRI. (D) MRI images of pre- and post-treatment mouse lungs. (E) H&E
staining showing the histology of the lungs from treatment-naïve, osimertinib-treated and healthy mice.
Scale bar: 100μm.
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Figure 4.2 Isolation of mKate+ cells from the GEMM. (A) IHC staining for EGFR L858R mutant and
mKate. Scale bar: 50μm. (B) Number of mKate+ cells isolated from tumor-bearing mice after
osimertinib treatment for 4 or 6 weeks and from healthy mice. (C) Flow charts showing the presence of
mKate+ cells in mouse lungs both before and after treatment. The genotypes and drug treatment
schedules of the mice exemplified in each group are listed below each flow chart.
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Figure 4.3 Transcriptomic profiling of mKate+ cells isolated from the GEMM. (A) Experimental
schema for molecular profiling of mKate+ cells isolated in various conditions. (B) PCA plot showing the
differences in gene expression profiles of mKate+ cells between healthy, untreated and osimertinibtreated groups. (C) Results of MetaCore pathway analysis showing the pathways up- or
downregulated in osimertinib-treated mKate+ cells as compared to untreated cells.
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DISCUSSION
The transgenic mouse model of mutant EGFR lung cancer provides further insights into
mechanisms of TKI tolerance, which are complimentary to the PDX models as discussed in
Chapter 2 and 3. We performed different types of NGS for the tumor cells collected from the two
models and profiled the molecular properties of drug tolerant residual disease in vivo. One
prominent feature identified through DNA sequencing that is shared across different mouse
models is lack of resistance conferring mutations in both pre- and post-TKI treatment tumor
cells. In PDXs, we identified neither osimertinib resistant mutations in EGFR that emerged
following treatment nor any dramatic changes in allelic frequency of already existing mutations
in residual disease compared to untreated tumors. In GEMMs, there was no selection or
enrichment of common mutations in EGFR transgene that cause resistance to first-, second- or
third-gen TKIs in DTRCs. These results suggest that at least in the models that we have
examined, TKI resistant mutations, if any, tend to develop de novo during treatment rather than
pre-exist in treatment-naïve tumors. To support this idea, studies of acquired resistance to
osimertinib in GEMMs suggest that it generally takes 5-6 months to obtain resistant tumor
nodules [23] and 4 weeks of TKI treatment is probably not sufficient for observing a dominant
clone with secondary mutations. The PDX models (YLR074 and YLR102) require even longer
period of treatment to develop acquired resistance. Pilot studies suggest that tumors were still
sensitive to osimertinib following treatment for about a year with drug-on and -off schedule.
Therefore, TKI resistant mutations are unlikely to be present at high frequency in persistent
tumor cells after only six weeks of treatment. Furthermore, in vitro analyses of human mutant
EGFR lung cancer cell lines indicated the presence of a subpopulation free of pre-existing drug
resistant T790M mutation, which developed acquired resistance and gained T790M mutation
after long-term treatment with first-gen EGFR TKI, indicating the possibility of de novo
mutagenesis given enough time of drug treatment [50].
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In the DTRCs isolated from GEMM, we identified an upregulated transcriptional program
that was related to cholesterol and fatty acid biosynthesis and controlled by the transcription
factor SREBP. This finding led to a hypothesis that changes in metabolic pathways could be
underlying the drug tolerant phenotypes in tumor cells. In fact, metabolic reprogramming has
been characterized in residual tumor cells following oncogene deprivation in transgenic mouse
models of breast cancer [111]. The tumor cells that persisted after cessation of oncogene
expression shifted to lipid metabolism, which resulted in production of higher levels of reactive
oxygen species (ROS) and altered redox balance within the cells. The metabolic shifts caused
increased accumulation of DNA damage mediated by ROS and eventual tumor recurrence. In
order to understand how SREBP-related transcriptional changes shape the metabolic status in
drug tolerant persisters, future experiments will be focused on profiling the regulators and
enzymes in different metabolic pathways to determine the relationship between metabolic
reprogramming and survival of DTRCs.
The Cre recombinase-mediated conditional rtTA expression system in this refined GEMM
can be adapted in various ways. When combined with lentiviral-Cre and other genetic tools, this
model enables direct genetic modifications and cell barcoding in mouse lung tumor cells.
Recent CRISPR screening studies in the GEMM of mutant EGFR lung cancer revealed the
possibility to edit multiple tumor suppressor genes simultaneously and compare tumor
development and TKI responses in different genetic contexts [110]. A refined model like this is
useful in terms of investigating the biology of drug tolerant persisters in the presence of various
co-occurring mutations identified in lung cancer patients.
In the GEMM that we discussed in this chapter, we identified mKate+ cells in tumor-bearing
mice with complete responses to osimertinib. One potential problem with this model, especially
when drug response is profound and tumor lesion is invisible, is that mKate-expressing cells
may not be transformed and retain the phenotypes of healthy epithelial cells. In the context of
drug tolerant residual disease, these mKate+ normal cells can be sorted out together with
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persister tumor cells, confounding the molecular profiling studies of drug tolerant mechanisms.
A potential solution to this problem is to perform single-cell sequencing on the isolated mKate+
cells to distinguish between healthy and tumor cells and to untangle the complexity resulting
from a mixed cell population.

EXPERIMENTAL PROCEDURES
Initiate tumor growth in the GEMM.
6-8 weeks old mice with appropriate genotypes were given two consecutive doses of
tamoxifen (Sigma-Aldrich, C5648) at 0.25mg/g to active Cre recombinase. Mice were then fed
with doxycycline diet (Envigo) to induce expression of oncogenic EGFR. Tumor development
was monitored by MRI until the mice were ready to be treated.
Tamoxifen was dissolved at 25mg/ml in corn oil (Sigma-Aldrich, C8267), with overnight
shaking.

Drug treatment in vivo.
Tumor-bearing mice were treated with osimertinib at 25mg/kg for five consecutive days each
week when their tumor size reached around 300-500mm3. The treatment lasted for 4 weeks
before mouse lungs harboring drug tolerant residual tumor was excised. Tumor burden was
measured by MRI at least once before treatment and once before sacrifice.

Magnetic resonance imaging.
Experimental details of magnetic resonance imaging on mice were described previously
[112]. In brief, mice were anesthetized and maintained on isoflurane/O2 (2–2.5% v/v)
throughout the imaging process. MR images were collected using a 4T small-animal Bruker
horizontal-bore spectrometer (Bruker AVANCE). MR data collection was synchronized with
animal respiration through a small-animal monitoring and gating system (SA Instruments, Inc),
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to make sure that all the images were captured during postexpiratory periods. Tumor burden
was determined by quantification of lung opacity area present in MR images using BioImage
Suite 3.01 [113].

Immunohistochemistry staining.
Experimental details are the same as described in chapter 2.
Primary antibodies used for IHC: EGFR L858R mutant (CST, 3197, 1:100), mKate (Evrogen,
AB233, 1:1000).

Sorting of mKate+ cells.
Mouse lungs excised from mice with desired genotypes and receiving appropriate
treatments were processed with mouse lung dissociation kit (Miltenyi Biotech, 130-095-927).
The single-cell suspension was subjected to FACS to identify and isolate mKate+ cells, based
on the gating strategy shown in Figure 4.2C.

Targeted deep sequencing for EGFR transgene.
Genomic DNA was extracted from sorted mKate+ cells with AllPrep DNA/RNA Micro Kit
(Qiagen, 80284) and used as template to amplify two coding regions in mutant EGFR
transgene: cDNA 2065-2355 and 2337-2604, which cover the common TKI resistant mutations
in EGFR kinase domain. The PCR was performed with HotStarTaq Master Mix Kit (Qiagen,
203443). Sequencing libraries were prepared from PCR products with KAPA HyperPrep Kit
(Kapa Biosystems, KK8504), KAPA Dual-Indexed Adapter Kit (Kapa Biosystems, KK8722), and
KAPA Pure Beads (Kapa Biosystems, KK8000). The libraries were pooled and sequenced on
illumina NovaSeq 6000 sequencer at YCGA to generate 150bp paired end reads. The raw
sequencing reads were first aligned to the EGFR amplicon sequences using the Burroughs-
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Wheeler aligner [72], and an in-house script was used to calculate the allelic frequency at each
position seen in the amplicon reference.

Bulk RNA-sequencing.
Total RNA was extracted from sorted mKate+ cells with AllPrep DNA/RNA Micro Kit
(Qiagen, 80284). RNA integrity was determined by running an Agilent Bioanalyzer gel, which
measures the ratio of the ribosomal peaks. Samples with RIN values of 7 or greater proceeded
to library prep. RNA-seq libraries were constructed using SMART-Seq v4 Ultra Low Input RNA
Kit (Takara Bio) and sequenced on illumina HiSeq2500 sequencer using 75bp single-end
sequencing to generate around 30M reads per sample.

Bulk RNA-sequencing data analysis.
Low quality reads were trimmed and adaptor contamination were removed using Trim
Galore (v0.5.0, https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed
reads were mapped to the mouse reference genome (mm10) using HISAT2 (v2.1.0) [99]. Gene
expression levels were quantified using StringTie (v1.3.3b) [100] with annotations based on
gene models (vM15) from the GENCODE project. Differentially expressed genes were identified
using DESeq2 (v 1.22.1) [80].

Pathway enrichment analysis.
Experimental details are the same as described in chapter 2.
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Figure S4.1 Tumor-bearing transgenic mice of mutant EGFR LUAD showed partial responses to
erlotinib. (A) Tumor burden in erlotinib-treated mice as measured by MRI. (B) MRI images of pre- and
post-treatment mouse lungs. (C) Waterfall plot showing the degree of drug response in osimertiniband erlotinib-treated mice.
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Figure S4.2 On-target resistance conferring EGFR mutations were not enriched in mKate+ cells
isolated from TKI-treated GEMM. Bar plots showing the frequency of wildtype alleles at the codon
encoding EGFR mutations known to confer resistance to first-, second- and third-generation EGFR
TKIs in mKate+ cells sorted from untreated and TKI-treated mice. EGFR L858R mutation was
analyzed as a positive control and the bar plot for L858R showed the frequency of mutant allele.
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Table S4.1 Expression of lung epithelial markers in mKate+ cells isolated from healthy,
untreated and osimertinib-treated mice.
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CLOSING REMARKS
Incomplete response to therapies occurs in nearly all types of cancer. In many cases, tumor
lesions in patients receiving anti-tumor agents initially undergo regression, followed by an
intermediate drug tolerant stage where tumor burden remains constant as treatment continues
with eventual tumor progression (acquired resistance). In mutant EGFR-driven lung cancer for
which targeted therapy is available, residual disease is a major challenge since acquired
resistance to EGFR TKIs is inevitable and the main reason for treatment failure. Studies on drug
tolerant persisters in TKI-treated lung cancer cell lines have broadened our knowledge about
the biology of persister cells in vitro. Further investigation of residual disease from a more
clinically and physiologically relevant perspective will deepen our understanding about drug
tolerant mechanisms in vivo and shed light on the evolution of acquired resistance in more
detail. To pursue this and gain insights into the biology of residual disease, we studied the
biological properties of drug tolerant residual disease in PDX mouse models, which more
resembled the complexity and diversity of clinical specimens than established cell lines.
In the three PDXs that we characterized in my thesis project, two of them showed
incomplete tumor regression in response to the third-generation TKI osimertinib, which
mimicked the residual disease observed in mutant EGFR lung cancer patients receiving EGFR
TKIs. The cellular features of persistent tumor cells included cell cycle arrest and low levels of
apoptosis, as evidenced by IHC staining for proliferation and apoptosis markers. To identify
mechanisms underlying TKI tolerance in DTRCs, we examined the genomic and transcriptomic
profiles of residual tumor cells and explored the changes in the mutational landscape and gene
expression before and after osimertinib treatment. As indicated by WES, the mutational
landscape remained very similar between untreated tumor and residual disease. However, gene
expression profiling revealed a number of differentially expressed genes in residual tumor cells
compared to the untreated ones in both PDXs, indicating that transcriptional rather than genetic
mechanisms potentially accounted for TKI tolerance in persister cells.
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Close examination of gene expression data for PDX tumor samples led to identification of
ASCL1 upregulation in one of the PDXs post-osimertinib treatment. Gene-set enrichment
analysis suggested that ASCL1 functioned as a transcription factor and a gene signature
associated with it was induced in the residual cells. To understand how the tumor cells evolved
into DTRCs during TKI therapy, we performed single-cell RNA-sequencing for untreated and
residual tumor cells, which revealed the presence of a pre-existing DTRC-like subpopulation in
untreated tumors characterized by high expression of ASCL1. The intratumoral heterogeneity
identified in PDXs raised the possibility that residual cells resulted from the selection of a
subpopulation with drug tolerant state by EGFR TKIs.
Subsequent functional and mechanistic studies demonstrate that ASCL1 overexpression led
to osimertinib tolerance in one out of the three mutant EGFR lung adenocarcinoma cell lines
that we tested. In the cell line that showed TKI tolerant phenotypes but not in the others, ectopic
expression of ASCL1 induced morphological changes and an EMT gene signature, indicating a
context-dependent role of ASCL1 in driving phenotypic changes in EGFR mutant lung cancer.
In addition to studying PDX models, to get a more comprehensive understanding of
mechanisms of TKI tolerance, we also interrogated the biological features of drug tolerant
persister cells in an immune-competent GEMM of EGFR mutant lung cancer in which lung
epithelial cells were labeled with fluorescent marker to enable FACS. Transcriptomic profiling of
the mKate+ cells isolated from mice before and after TKI treatment by RNA-seq indicated a
variety of deregulated gene expression programs in residual cells, which were involved in
regulatory and survival pathways, including upregulation of cholesterol/fatty acid biosynthesis
and NOTCH signaling pathway, as well as downregulation of cell cycle-related pathways and
HIF1α-regulated program. Further studies to understand the biological implications of
deregulation of these pathways remain to be performed.
Despite all the in vivo and in vitro findings that lead to deeper insights into residual disease
in EGFR-driven lung cancer, questions regarding the connections between drug tolerance and
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acquired resistance and the therapeutic approaches to target residual tumor cells still remained
to be addressed.

Evolving from drug tolerant residual disease into acquired resistance.
Five EGFR TKIs have been approved as the first-line treatment for EGFR mutant lung
cancer, however acquired resistance inevitably occurs in patients receiving any of these drugs.
On-target resistance conferring mutations in EGFR are the major mechanisms of resistance for
all of the three generations of TKIs [30, 33, 34, 36]. Although previous studies have
demonstrated that the T790M mutation, for example, can pre-exist in TKI-naïve tumors at low
frequency and become enriched following treatment with first-generation TKIs, T790M- tumor
cells can still survive TKI treatment as drug tolerant persisters and eventually develop such
resistance mutation de novo [50]. Drug tolerant residual disease acts as an intermediate stage
between pre-treatment tumor and acquired resistance and understanding its mutational
landscape thus provides insights into how the resistance-conferring mutations come into
existence. In either the PDX models or the GEMM that we studied in this thesis project, the ontarget EGFR mutations were not identified in residual tumor cells and the overall mutational
landscape remained largely unchanged compared to untreated tumors. Indeed, increasing
evidence suggests that TKI tolerance in EGFR mutant lung cancer is caused by epigenetic
mechanisms and transcriptional changes rather than resistance conferring mutations [41, 44,
47]. The absence of genetic drivers in TKI tolerant cells suggests that mutagenesis is a
relatively inefficient process and it takes a long time for the right gene target to become mutated
and for drug resistant clones to become dominant in recurrent tumors. In the mouse models
described in previous chapters, the residual tumor cells were collected following only 1-2
months of TKI treatment, which was likely to be still at an early stage considering the time frame
during which acquired resistance usually developed (~1.5 years for osimertinib). Further
characterization of residual tumor cells collected longitudinally along the treatment course would
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provide more evidence to elucidate when certain resistance-associated genetic events occur in
the genome.
Phenotypic transition and histological transformation constitute another big category of
mechanisms of TKI resistance, for which detailed evolutionary processes remain poorly
understood. We identified upregulation of a neuroendocrine lineage factor ASCL1 in postosimertinib residual tumors from one of the PDX models that we examined, albeit without
significant neuroendocrine phenotypes. Given the role of ASCL1 as a neuroendocrine lineage
transcription factor, the residual disease in that PDX might represent a transition state prior to
the acquisition of neuroendocrine features. RB1 has been implicated as being commonly
mutated in TKI-resistant tumors with SCLC transformation [114]. Therefore, one hypothesis is
that histological transformation requires the presence of additional genetic alterations like RB1
loss and functional studies in PDX and cells are underway to prove this.

Upstream regulators for ASCL1 in EGFR mutant lung cancer.
Gene expression profiling through bulk RNA-sequencing and single-cell RNA-sequencing
indicated enrichment of an ASCL1 gene signature in TKI tolerant residual cells and a preexisting subpopulation of untreated tumor cells from one PDX in our cohort. Despite the fact that
a subset of lung adenocarcinomas are characterized by ASCL1 positivity [93], it still remains
unclear what upstream regulators and/or pathways mediate ASCL1 expression in these LUAD
cases. In the context of SCLC, the histone demethylase KDM5A has been shown to sustain
ASCL1 expression through suppression of NOTCH signaling activity, highlighting an epigenetic
mechanism underlying the maintenance of the NE differentiation state [97]. As future directions,
we would like to determine the role of KDM5A as well as other epigenetic regulators in
mediating ASCL1 expression and whether or not they can affect lineage transition in PDXs and
cell lines of EGFR mutant lung cancer. Ongoing experiments are designed to overexpress
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ASCL1 in established human cell lines, followed by functional testing including target gene
expression, drug sensitivity and clonogenic assay.

Targeting drug tolerant residual disease to delay acquired resistance.
One of the reasons for studying mechanisms of drug tolerance is to identify drug targets to
repress or eliminate persister cells to delay or prevent the emergence of acquired resistance.
Based on the results from this thesis project, we identified ASCL1 as a driver of TKI tolerance in
mutant EGFR lung cancer. Studies in SCLC have provided clear evidence that ASCL1 is a
critical regulator of NE differentiation and required for tumor initiation and maintenance [89, 92,
97, 98]. In addition, SCLC transformation is one of the common TKI resistance mechanisms.
Therefore, targeting ASCL1 could be of potential use in treating patients with incomplete
response to EGFR TKIs and upregulation of ASCL1 in residual cells. As ASCL1 functions as a
transcription factor, developing its small molecule inhibitor is proved to be challenging.
Alternative strategies include identifying druggable targets among upstream regulators and
downstream gene targets of ASCL1. One canonical target gene regulated by ASCL1 encodes
the anti-apoptotic protein BCL2, for which BH3-mimetic small molecule venetoclax has been
approved to treat cancers dependent on the anti-apoptotic effects of BCL2 [115, 116]. The
combination of EGFR TKIs and BCL2 inhibitors could be used as a follow-up treatment for
leftover tumor cells after initial targeted therapy [45]. Another ASCL1-targeting strategy under
development is to directly modulate its protein levels. Depending on the chemical nature of a
gene product, it is possible to design protein degraders that target either the protein-of-interest
(POI) itself or its binding partners that stabilize the POI. Recent genetic and chemical screening
identified CDK2 as a stabilizer of ASCL1 protein and degradation of CDK2 by PROTAC reduced
ASCL1 protein levels, providing a potential strategy to suppress ASCL1+ TKI tolerant residual
cells [117].
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